www.TheFinancialMarketingGroup.com
Followers | 59 |
Posts | 2,197 |
Boards Moderated | 4 |
Alias Born | 04/28/2019 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
XLM Retracement Complete? Key Fib Level Hit
XLM has retraced nicely down to the 0.7 ranges on the FIB.
However with decreasing volume it will be tough to see if it will expect a move up or not.
MACD is starting to look more bullish with an uptick on the histogram but still not enough confirmations on the RSI yet.
We are waiting to see if more confirmations are going to come through and a trend holds. Waiting to see what happens to XRP too as it can follow that too.
XLM Retracement Complete? Key Fib Level Hit
XLM has retraced nicely down to the 0.7 ranges on the FIB.
However with decreasing volume it will be tough to see if it will expect a move up or not.
MACD is starting to look more bullish with an uptick on the histogram but still not enough confirmations on the RSI yet.
We are waiting to see if more confirmations are going to come through and a trend holds. Waiting to see what happens to XRP too as it can follow that too.
NLBIF is our fresh low-float cannabis play w/ massive potential
========================
NLBIF (NewLeaf Brands Inc.)
Alert Price: $0.5744
Chart Analysis
Corporate Presentation
Website | Recent News
eCommerce: http://www.wearekured.com
========================
Members,
Over the last 12 months, there has been tremendous hype on cannabis stocks. The widespread legalization in some states in the U.S. and all of Canada caused many stocks related to the pot industry to skyrocket. The surge has been deemed by some as the new gold rush. If you feel like you got left behind, don’t worry.
Some cannabis stocks have corrected over the last few months, and they’re ready to be bought on dips.
One such company is NLBIF (NewLeaf Brands Inc.).
Trading well off its 52-week high of $0.8765, this microcap cannabis company has much more upside potential that some of the more well known companies in their sector.
About NewLeaf Brands
NewLeaf Brands is an innovative Cannabidiol (“CBD”) lifestyle Company. Through the Company’s wholly owned subsidiaries We are Kured and Drink Fresh Water, the Company’s main business activities encompass the development, marketing and distribution of CBD products (including vaporizer pens and beverages) throughout the United States and internationally. In addition, NewLeaf Brands has extensive retail and cultivation land investments in Oregon.
For further information about NewLeaf Brands, please consult the Company’s profile on SEDAR at http://www.sedar.com or visit the Company’s website at http://www.NABrandsInc.com. For further information about We Are Kured, please visit their website at http://www.wearekured.com.
Global CBD Oil Market
Today the hemp/cannabis industry is fragmented, immature, and in many cases, poorly managed. It is a space that has never seen much in the way of real regulation, competition, or consumer demands for quality of service and product. As this industry matures and becomes mainstream, many businesses will have to contend with an environment in which they could not currently survive, and pressures they have never faced. The entry of large investment groups and significant corporate players will also represent a major paradigm shift in the space. They are preparing themselves for these eventualities, and believe they are building a business and a brand from day one to the very highest standards in every respect. It is the "picks & shovels" of the industry that often see higher margins and better sales. These areas of operations also give them the ability to build an internationally recognized brand. It is a strong belief that broader legalization and consumer acceptance of hemp/cannabis and all of its related products is underway. Beyond the medical reasons, there are an overwhelming number of economic, social, and political factors driving the growth of this marketplace. It is a certainty that hundreds of billions of dollars per year will be generated by this industry in the US alone. It is a certainty that many companies will be hugely successful in this space. NLBIF is positioning themselves to be one of these many successes.
Premium CBD Water
Fresh Water is a purified Alkaline rich water containing body essentials which include Hemp derived nano-amplifi ed CBD . Created by people living active lifestyles, Fresh Water is ultra refreshing, intended to elevate performance,
health, and wellness .
About Drink Fresh Water
Every bottle begins with purified alkaline water through reverse osmosis and is tested at time of bottling at pH9 for optimal beverage consumption.
Given the shown effects of our Hemp-Derived CBD , we chose to pair it with high performing Alkaline Water. Alkaline water is excellent in helping rehydrate better than other waters . Faster Recovery from CBD and Better Hydration from Alkaline
Water
Product
100% Hemp-Derived CBD Infused Beverage.
Non-psychoactive and THC free.
Enjoy all of the benefits CBD has to offer.
1 bottle - 16oz of CBD infused water
About KURED
KURED is a socially-minded lifestyle Full Spectrum hemp derived CBD company founded to help pave the way CBD is viewed internationally. KURED puts the customer first, providing the highest quality CBD oil . Based out of Colorado, USA, KURED was created with passion of spreading the powers of using full spectrum CBD oil . The company’s strategy is broken up into phases enabling the development of sales channels and relationships while systematically building the back end of the company in Hemp cultivation and extraction to ultimately be fully vertically integrated!
“We consider KURED a trendsetting Broad Spectrum Hemp Extract company, and we know we have the knowledge and passion to change the way people view Broad Spectrum Hemp Extract. We have partnered with some of the top cannabis formulators, cultivators and product manufacturers in the global cannabis industry to develop a variety of Hemp derived BSHE products. We are climbing to the top of our favorite industry, working to be leaders in hemp cultivation, because frankly, we know that quality products are what our clients expect…and it’s what we will provide.”! - Ben Martch - Founder & CEO
NLBIF has recently made some strategic acquisitions that could lead to a massive revenue increase for this up-and-coming company.
NewLeaf Brands Signs Binding LOI to Acquire TeaLief Brand, LLC
In late June, the Company announced that it has entered into a binding letter of intent (the “LOI”) with TeaLief Brand, LLC (“TeaLief”). Under the terms of the LOI, the Company will acquire 100% of the issued and outstanding shares of TeaLief (the “Acquisition”). In consideration for the Acquisition, the Company will pay to TeaLief an aggregate amount of $3,000,000 USD in the form of common shares in the capital of the Company. The share price is to be set on the closing price as of the date of signing of the LOI. The Acquisition is expected to close within 60-90 days of submission. Closing is subject to definitive documentation and applicable regulatory approvals.
TeaLief, a Colorado based company, designs, manufactures, and sells a line of high quality, fully organic CBD infused teas. Currently the company has three product offerings: Black Ginger Peach (a high caffeine offering) Green Tea Coconut (a mild caffeine offering) and Honey Spice Rooibos (a zero caffeine offering).
“We are extremely excited at the potential to add TeaLief to our list of brands,” stated Josh Bartch CEO of NewLeaf Brands. “The craftsmanship that has gone into designing this product is truly paramount. When our team tried these organic teas, we were truly blown away. We also feel that this product can be offered at a number of big box retailers that are becoming friendlier to the thought of carrying CBD infused products. This transaction represents the first of what we expect to be many new companies that will be joining the NewLeaf portfolio in the very near future,” Josh concluded
NewLeaf Brands Signs Binding LOI to Acquire ReLyfe Brand, LLC
2 weeks ago, NLBIF announced that it has entered into a binding letter of intent (the “LOI”) with ReLyfe Brand, LLC (“ReLyfe”). Under the terms of the LOI, the Company will acquire 100% of the issued and outstanding shares of ReLyfe (the “Acquisition”). In consideration for the Acquisition, the Company will pay to Relyfe an aggregate amount of $3,000,000 USD in the form of common shares in the capital of the Company. The share price is to be set on the closing price as of the date of signing of the LOI. The Acquisition is expected to close within 60-90 days of submission. Closing is subject to definitive documentation and applicable regulatory approvals.
ReLyfe is a health-focused gel capsule CBD company manufactured and based out of Colorado, USA. ReLyfe was founded to provide high quality, simple to take, effective and non-habit forming healthy alternative to traditional medication on the market today. ReLyfe’s THC FREE CBD gel capsules are changing the way many consumers view hemp-derived CBD because the gel capsules provide a safe, easy, and discrete alternative to traditional ways that CBD is enters your system. ReLyfe offers 3 different sized product offerings: a 2-day starter pack, a 7-day week pack, and a 30-day monthly bottle. ReLyfe’s products are currently available in stores both in the US and internationally.
“As I’ve stated before, we have been actively looking for the best products and companies to add under our umbrella of companies,” said Josh Bartch, CEO of NewLeaf Brands. “This potential purchase of ReLyfe further solidifies our plan to accomplish that moving forward,” Josh continued. “We have looked at a number of companies that manufacture or offer a pill product of some sort; none of them hold a candle to the quality of ReLyfe’s product. Based on our extensive research, a pill form of CBD is one of the top selling products in the industry as it stands, we expect this to only continue. As we continue to expand both our current distribution channels through We Are Kured LLC and Fresh Water, LLC, we are able to feed our newly added high quality products into each and every line of distribution. We intend on updating our loyal shareholders on other milestones the Company has reached over recent months as well as what to look for in the future. Needless to say we are very excited,” Josh concluded.
Recent Developments:
NewLeaf Brands Signs Exclusive Distribution Agreement With Best Strains, LLC
Today NLBIF announced that it has entered into an exclusive distribution agreement (the “Agreement”) with Best Strains, LLC (“Best Strains”) based out of Tennessee, USA. Under the terms of the Agreement, Newleaf Brands will have the rights for distribution of their KURED disposable vape pens, vape cartridges and Fresh Water to convenient stores, liquor stores, novelty/tourist retailers, and other big box retailers throughout Tennessee.
Best Strains was founded by the same family that has been in the wholesale wine, beer, beverage and spirits distribution business since 1939 and is currently distributing to over 3000+ retail locations.
Jason Eskind, Executive Vice President of Best Strains, who is 4th generation to founder Manual Eskind stated, “We are extremely excited to be entering this new market segment with a strong brand and partner in NewLeaf Brands.”
Chief Marketing Officer of Newleaf Brands, Benjamin Martch, commented, “Being that Tennessee is a hub for hemp cultivation, we have been working on getting a distribution agreement with a notable company like Best Strains, LLC for the last few months. Their current partner’s products are being sold in stores throughout the Tennessee market, and we cannot wait to see what they can do with KURED!”
Market Outlook:
The cannabis market has grown at a tremendous pace over the recent years and as such, the industry has established itself a major global market. According to data compiled by Grand View Research, the global legal cannabis market is projected to reach USD 146.4 Billion by the 2025. It is also expected to grow at a CAGR of 34.6%. The market itself is witnessing a widespread legalization movement due to the growing adoption of the plant within the medical sector. Cannabis is being used heavily around the global for medical applications and treatments for maladies such as cancer, mental disorders, chronic pain, and others. However, the recreational market is thriving as well due specifically to the U.S. and Canada. States like California, Colorado, and Nevada are expected to propel the recreational sector forward at an encouraging rate.
The acceleration of research and development has led to new products within the market, enhancing consumer experiences. The research suggests that the industry is expecting strong exchanges of technological knowledge and information. Meanwhile, as countries like Canada, the U.S., Germany, and Australia lead the market in sales, countries like Israel are focusing on research and technology development to further expand within the industry. Additionally, there are various new forms of technology being introduced into the cannabis sector, such as virtual reality, payment solutions, and medical devices. "That's why we firmly believe that technology stands at the center of the industry's advancement and growth," said Ben Curren Chief Executive Officer of Green Bits, "This innovation will continue to generate market growth, improve public perception, protect public health and safety and enhance the implementation of state programs and regulations.
CBD is becoming widely accepted by consumers and countries. For example, in the U.S., CBD became legal after the Farm Bill that passed in late 2018.
That in mind, consumers could easily find CBD products across the U.S. In turn, we may actually see some CBD companies generating more revenues and earnings than cannabis companies.
Now, investment bank Cowen & Co. analysts estimate that the CBD market will reach $16B by 2025.
That said, CBD companies could experience exponential growth rates with such a large market. Not only that, large-cap drug stores like CVS and Walgreens have bet on CBD .
Additionally, CVS and Walgreens noted they would offer CBD products in more than 2,000 stores across the U.S.
But these companies need to find a reputable source for CBD products. Now, there’s one little-known company focused on CBD and offers an array of high-quality CBD-only products. With CVS and Walgreens offering CBD products, it wouldn’t be surprising to see either of these two large drug store companies to strike a partnership, invest in, or even acquire this CBD company.
Technical Analysis:
Like many of our past winners, this low-float alert has a proven history of massive intraday swings.
In the last two trading sessions alone, NLBIF had made intraday swings of +45% and +25% respectively!
With tomorrow's anticipated increase in trade volume , we are expecting a much bigger move from NLBIF.
In fact, we've done our very own chart analysis, and see the potential for a move of over +160%!
If you're on the hunt for the next breakout cannabis stock, then NLBIF should be the only ticker on your radar tomorrow.
That being said, we ask that all members start their research on NLBIF immediately, and consider building a position tomorrow morning at 9:30AM EST
(*Remember to use a Basic Stop-Loss Order or more advanced Stop Limit Order to protect your gains, as well as limit possible losses.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Media Group for a 1-day investor relations advertising marketing campaign w/ 1000 TradingView™ views for NLBIF. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
NLBIF is our fresh low-float cannabis play w/ massive potential
========================
NLBIF (NewLeaf Brands Inc.)
Alert Price: $0.5744
Chart Analysis
Corporate Presentation
Website | Recent News
eCommerce: http://www.wearekured.com
========================
Members,
Over the last 12 months, there has been tremendous hype on cannabis stocks. The widespread legalization in some states in the U.S. and all of Canada caused many stocks related to the pot industry to skyrocket. The surge has been deemed by some as the new gold rush. If you feel like you got left behind, don’t worry.
Some cannabis stocks have corrected over the last few months, and they’re ready to be bought on dips.
One such company is NLBIF (NewLeaf Brands Inc.).
Trading well off its 52-week high of $0.8765, this microcap cannabis company has much more upside potential that some of the more well known companies in their sector.
About NewLeaf Brands
NewLeaf Brands is an innovative Cannabidiol (“CBD”) lifestyle Company. Through the Company’s wholly owned subsidiaries We are Kured and Drink Fresh Water, the Company’s main business activities encompass the development, marketing and distribution of CBD products (including vaporizer pens and beverages) throughout the United States and internationally. In addition, NewLeaf Brands has extensive retail and cultivation land investments in Oregon.
For further information about NewLeaf Brands, please consult the Company’s profile on SEDAR at http://www.sedar.com or visit the Company’s website at http://www.NABrandsInc.com. For further information about We Are Kured, please visit their website at http://www.wearekured.com.
Global CBD Oil Market
Today the hemp/cannabis industry is fragmented, immature, and in many cases, poorly managed. It is a space that has never seen much in the way of real regulation, competition, or consumer demands for quality of service and product. As this industry matures and becomes mainstream, many businesses will have to contend with an environment in which they could not currently survive, and pressures they have never faced. The entry of large investment groups and significant corporate players will also represent a major paradigm shift in the space. They are preparing themselves for these eventualities, and believe they are building a business and a brand from day one to the very highest standards in every respect. It is the "picks & shovels" of the industry that often see higher margins and better sales. These areas of operations also give them the ability to build an internationally recognized brand. It is a strong belief that broader legalization and consumer acceptance of hemp/cannabis and all of its related products is underway. Beyond the medical reasons, there are an overwhelming number of economic, social, and political factors driving the growth of this marketplace. It is a certainty that hundreds of billions of dollars per year will be generated by this industry in the US alone. It is a certainty that many companies will be hugely successful in this space. NLBIF is positioning themselves to be one of these many successes.
Premium CBD Water
Fresh Water is a purified Alkaline rich water containing body essentials which include Hemp derived nano-amplifi ed CBD . Created by people living active lifestyles, Fresh Water is ultra refreshing, intended to elevate performance,
health, and wellness .
About Drink Fresh Water
Every bottle begins with purified alkaline water through reverse osmosis and is tested at time of bottling at pH9 for optimal beverage consumption.
Given the shown effects of our Hemp-Derived CBD , we chose to pair it with high performing Alkaline Water. Alkaline water is excellent in helping rehydrate better than other waters . Faster Recovery from CBD and Better Hydration from Alkaline
Water
Product
100% Hemp-Derived CBD Infused Beverage.
Non-psychoactive and THC free.
Enjoy all of the benefits CBD has to offer.
1 bottle - 16oz of CBD infused water
About KURED
KURED is a socially-minded lifestyle Full Spectrum hemp derived CBD company founded to help pave the way CBD is viewed internationally. KURED puts the customer first, providing the highest quality CBD oil . Based out of Colorado, USA, KURED was created with passion of spreading the powers of using full spectrum CBD oil . The company’s strategy is broken up into phases enabling the development of sales channels and relationships while systematically building the back end of the company in Hemp cultivation and extraction to ultimately be fully vertically integrated!
“We consider KURED a trendsetting Broad Spectrum Hemp Extract company, and we know we have the knowledge and passion to change the way people view Broad Spectrum Hemp Extract. We have partnered with some of the top cannabis formulators, cultivators and product manufacturers in the global cannabis industry to develop a variety of Hemp derived BSHE products. We are climbing to the top of our favorite industry, working to be leaders in hemp cultivation, because frankly, we know that quality products are what our clients expect…and it’s what we will provide.”! - Ben Martch - Founder & CEO
NLBIF has recently made some strategic acquisitions that could lead to a massive revenue increase for this up-and-coming company.
NewLeaf Brands Signs Binding LOI to Acquire TeaLief Brand, LLC
In late June, the Company announced that it has entered into a binding letter of intent (the “LOI”) with TeaLief Brand, LLC (“TeaLief”). Under the terms of the LOI, the Company will acquire 100% of the issued and outstanding shares of TeaLief (the “Acquisition”). In consideration for the Acquisition, the Company will pay to TeaLief an aggregate amount of $3,000,000 USD in the form of common shares in the capital of the Company. The share price is to be set on the closing price as of the date of signing of the LOI. The Acquisition is expected to close within 60-90 days of submission. Closing is subject to definitive documentation and applicable regulatory approvals.
TeaLief, a Colorado based company, designs, manufactures, and sells a line of high quality, fully organic CBD infused teas. Currently the company has three product offerings: Black Ginger Peach (a high caffeine offering) Green Tea Coconut (a mild caffeine offering) and Honey Spice Rooibos (a zero caffeine offering).
“We are extremely excited at the potential to add TeaLief to our list of brands,” stated Josh Bartch CEO of NewLeaf Brands. “The craftsmanship that has gone into designing this product is truly paramount. When our team tried these organic teas, we were truly blown away. We also feel that this product can be offered at a number of big box retailers that are becoming friendlier to the thought of carrying CBD infused products. This transaction represents the first of what we expect to be many new companies that will be joining the NewLeaf portfolio in the very near future,” Josh concluded
NewLeaf Brands Signs Binding LOI to Acquire ReLyfe Brand, LLC
2 weeks ago, NLBIF announced that it has entered into a binding letter of intent (the “LOI”) with ReLyfe Brand, LLC (“ReLyfe”). Under the terms of the LOI, the Company will acquire 100% of the issued and outstanding shares of ReLyfe (the “Acquisition”). In consideration for the Acquisition, the Company will pay to Relyfe an aggregate amount of $3,000,000 USD in the form of common shares in the capital of the Company. The share price is to be set on the closing price as of the date of signing of the LOI. The Acquisition is expected to close within 60-90 days of submission. Closing is subject to definitive documentation and applicable regulatory approvals.
ReLyfe is a health-focused gel capsule CBD company manufactured and based out of Colorado, USA. ReLyfe was founded to provide high quality, simple to take, effective and non-habit forming healthy alternative to traditional medication on the market today. ReLyfe’s THC FREE CBD gel capsules are changing the way many consumers view hemp-derived CBD because the gel capsules provide a safe, easy, and discrete alternative to traditional ways that CBD is enters your system. ReLyfe offers 3 different sized product offerings: a 2-day starter pack, a 7-day week pack, and a 30-day monthly bottle. ReLyfe’s products are currently available in stores both in the US and internationally.
“As I’ve stated before, we have been actively looking for the best products and companies to add under our umbrella of companies,” said Josh Bartch, CEO of NewLeaf Brands. “This potential purchase of ReLyfe further solidifies our plan to accomplish that moving forward,” Josh continued. “We have looked at a number of companies that manufacture or offer a pill product of some sort; none of them hold a candle to the quality of ReLyfe’s product. Based on our extensive research, a pill form of CBD is one of the top selling products in the industry as it stands, we expect this to only continue. As we continue to expand both our current distribution channels through We Are Kured LLC and Fresh Water, LLC, we are able to feed our newly added high quality products into each and every line of distribution. We intend on updating our loyal shareholders on other milestones the Company has reached over recent months as well as what to look for in the future. Needless to say we are very excited,” Josh concluded.
Recent Developments:
NewLeaf Brands Signs Exclusive Distribution Agreement With Best Strains, LLC
Today NLBIF announced that it has entered into an exclusive distribution agreement (the “Agreement”) with Best Strains, LLC (“Best Strains”) based out of Tennessee, USA. Under the terms of the Agreement, Newleaf Brands will have the rights for distribution of their KURED disposable vape pens, vape cartridges and Fresh Water to convenient stores, liquor stores, novelty/tourist retailers, and other big box retailers throughout Tennessee.
Best Strains was founded by the same family that has been in the wholesale wine, beer, beverage and spirits distribution business since 1939 and is currently distributing to over 3000+ retail locations.
Jason Eskind, Executive Vice President of Best Strains, who is 4th generation to founder Manual Eskind stated, “We are extremely excited to be entering this new market segment with a strong brand and partner in NewLeaf Brands.”
Chief Marketing Officer of Newleaf Brands, Benjamin Martch, commented, “Being that Tennessee is a hub for hemp cultivation, we have been working on getting a distribution agreement with a notable company like Best Strains, LLC for the last few months. Their current partner’s products are being sold in stores throughout the Tennessee market, and we cannot wait to see what they can do with KURED!”
Market Outlook:
The cannabis market has grown at a tremendous pace over the recent years and as such, the industry has established itself a major global market. According to data compiled by Grand View Research, the global legal cannabis market is projected to reach USD 146.4 Billion by the 2025. It is also expected to grow at a CAGR of 34.6%. The market itself is witnessing a widespread legalization movement due to the growing adoption of the plant within the medical sector. Cannabis is being used heavily around the global for medical applications and treatments for maladies such as cancer, mental disorders, chronic pain, and others. However, the recreational market is thriving as well due specifically to the U.S. and Canada. States like California, Colorado, and Nevada are expected to propel the recreational sector forward at an encouraging rate.
The acceleration of research and development has led to new products within the market, enhancing consumer experiences. The research suggests that the industry is expecting strong exchanges of technological knowledge and information. Meanwhile, as countries like Canada, the U.S., Germany, and Australia lead the market in sales, countries like Israel are focusing on research and technology development to further expand within the industry. Additionally, there are various new forms of technology being introduced into the cannabis sector, such as virtual reality, payment solutions, and medical devices. "That's why we firmly believe that technology stands at the center of the industry's advancement and growth," said Ben Curren Chief Executive Officer of Green Bits, "This innovation will continue to generate market growth, improve public perception, protect public health and safety and enhance the implementation of state programs and regulations.
CBD is becoming widely accepted by consumers and countries. For example, in the U.S., CBD became legal after the Farm Bill that passed in late 2018.
That in mind, consumers could easily find CBD products across the U.S. In turn, we may actually see some CBD companies generating more revenues and earnings than cannabis companies.
Now, investment bank Cowen & Co. analysts estimate that the CBD market will reach $16B by 2025.
That said, CBD companies could experience exponential growth rates with such a large market. Not only that, large-cap drug stores like CVS and Walgreens have bet on CBD .
Additionally, CVS and Walgreens noted they would offer CBD products in more than 2,000 stores across the U.S.
But these companies need to find a reputable source for CBD products. Now, there’s one little-known company focused on CBD and offers an array of high-quality CBD-only products. With CVS and Walgreens offering CBD products, it wouldn’t be surprising to see either of these two large drug store companies to strike a partnership, invest in, or even acquire this CBD company.
Technical Analysis:
Like many of our past winners, this low-float alert has a proven history of massive intraday swings.
In the last two trading sessions alone, NLBIF had made intraday swings of +45% and +25% respectively!
With tomorrow's anticipated increase in trade volume , we are expecting a much bigger move from NLBIF.
In fact, we've done our very own chart analysis, and see the potential for a move of over +160%!
If you're on the hunt for the next breakout cannabis stock, then NLBIF should be the only ticker on your radar tomorrow.
That being said, we ask that all members start their research on NLBIF immediately, and consider building a position tomorrow morning at 9:30AM EST
(*Remember to use a Basic Stop-Loss Order or more advanced Stop Limit Order to protect your gains, as well as limit possible losses.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Media Group for a 1-day investor relations advertising marketing campaign w/ 1000 TradingView™ views for NLBIF. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
BTC to $13K Again?
Will we see a $13,000 BTC again.
The previous published idea on BTC showed that it was possible as a move up with a 3rd wave impulse on the 6 hour. Looking good so far with a move up into the $12,600 regions.
FOMO could go crazy with BTC if people decide to dump their alt-coins to jump into BTC and it will most likely smash through All-Time Highs again.
Be careful, Don't be fomoing.
BTC to $13K Again?
Will we see a $13,000 BTC again.
The previous published idea on BTC showed that it was possible as a move up with a 3rd wave impulse on the 6 hour. Looking good so far with a move up into the $12,600 regions.
FOMO could go crazy with BTC if people decide to dump their alt-coins to jump into BTC and it will most likely smash through All-Time Highs again.
Be careful, Don't be fomoing.
ETH 4th Wave Before Big 5th?
Looks like ETH is coming into a 4th corrective wave down before a 5th impulse up.
If this is going to continue in USD with BTC it seems likely that it would test those yearly highs so far.
ETH always runs with BTC in USD value but at the moment it is a little off but it seems to add up to the fact that this is a corrective wave.
Wait to see what level it will hit and look for a long position if it turns around.
ETH 4th Wave Before Big 5th?
Looks like ETH is coming into a 4th corrective wave down before a 5th impulse up.
If this is going to continue in USD with BTC it seems likely that it would test those yearly highs so far.
ETH always runs with BTC in USD value but at the moment it is a little off but it seems to add up to the fact that this is a corrective wave.
Wait to see what level it will hit and look for a long position if it turns around.
Antero Resources Corp Analyst warns Short Sellers.
ANALYSTS WARNS OF SHORTING INTO EARNINGS
Antero Resources, Range Resources analyst commentary at Stifel Short-selling Antero into earnings 'could be quite risky,' says Stifel. Stifel analyst Jane Trotsenko said investors could be inclined to short Antero Resources (AR) and Range Resources ( RRC ) given that Mt. Belvieu, Texas NGL prices are down 15% per barrel quarter-over-quarter. However, the analyst, who is projecting a production beat and "very healthy natural gas price realizations" from Antero thinks short-selling the stock into the earnings "could be quite risky," she tells investors in a research note. Antero also plans to update guidance with its Q2 report, "which makes this quarter particularly tricky," added Trotsenko, who keeps a Buy rating on the stock
COMPANY PROFILE
Antero Resources Corp. is an independent oil and natural gas company, which engages in the exploration, development and acquisition of natural gas , natural gas liquids and oil properties located in the Appalachian Basin. It also focuses on unconventional reservoirs, which can generally be characterized as fractured shales formations. The company was founded by Paul M. Rady and Glen C. Warren, Jr. in June 2002 and is headquartered in Denver, CO.
Antero Resources Corp Analyst warns Short Sellers.
ANALYSTS WARNS OF SHORTING INTO EARNINGS
Antero Resources, Range Resources analyst commentary at Stifel Short-selling Antero into earnings 'could be quite risky,' says Stifel. Stifel analyst Jane Trotsenko said investors could be inclined to short Antero Resources (AR) and Range Resources ( RRC ) given that Mt. Belvieu, Texas NGL prices are down 15% per barrel quarter-over-quarter. However, the analyst, who is projecting a production beat and "very healthy natural gas price realizations" from Antero thinks short-selling the stock into the earnings "could be quite risky," she tells investors in a research note. Antero also plans to update guidance with its Q2 report, "which makes this quarter particularly tricky," added Trotsenko, who keeps a Buy rating on the stock
COMPANY PROFILE
Antero Resources Corp. is an independent oil and natural gas company, which engages in the exploration, development and acquisition of natural gas , natural gas liquids and oil properties located in the Appalachian Basin. It also focuses on unconventional reservoirs, which can generally be characterized as fractured shales formations. The company was founded by Paul M. Rady and Glen C. Warren, Jr. in June 2002 and is headquartered in Denver, CO.
Acura Pharma is setting up to Breakout after today's 23% gain.
ACURA PHARMACEUTICALS IN. (OTC ACUR ) What a lovely trade this is setting up to be, everything is pointing to a breakout from a 1 year old channel of congestion, RSI , MON, MACD and Histogram are becoming bullish
and just like the price, entering a area of resistance. Because the stock has been so range bound for such a long time, any breakout will be amazing and fast, buys will be triggered and off it will go.
NOTEWORTHY ANNOUNCEMENT
https://www.benzinga.com/users/shanthi-r...
Acura Pharmaceuticals , Inc. (OTC: ACUR ) announced a licensing, development and commercialization agreement with Abuse Deterrent Pharma – a special purpose company representing a consortium of investors, which will finance the company's operations and completion of the development of LTX-03 immediate-release tablets using Acura's patented LIMITx technology.
The investigational drug addresses the consequences of excess oral administration of opioid tablets, the most prevalent route of opioid overdose and abuse.
The transaction is valued up to $21.3 million, not including royalties. The agreement also provides for Acura receiving royalties and potential sales-related milestones and AD Pharma retaining commercialization rights.
COMPANY PROFILE
Acura Pharmaceuticals Inc is a specialty pharmaceutical company based in the US. It is engaged in the research, development, and commercialization of technologies and products intended to address medication abuse and misuse. The company has developed Aversion and Limitx technologies are intended to address methods of abuse associated with opioid analgesics whereas Impede technology is directed at minimizing the extraction and conversion of pseudoephedrine (PSE), into methamphetamine. Its product line includes OXAYDO which is a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and other pipeline products.
Acura Pharma is setting up to Breakout after today's 23% gain.
ACURA PHARMACEUTICALS IN. (OTC ACUR ) What a lovely trade this is setting up to be, everything is pointing to a breakout from a 1 year old channel of congestion, RSI , MON, MACD and Histogram are becoming bullish
and just like the price, entering a area of resistance. Because the stock has been so range bound for such a long time, any breakout will be amazing and fast, buys will be triggered and off it will go.
NOTEWORTHY ANNOUNCEMENT
https://www.benzinga.com/users/shanthi-r...
Acura Pharmaceuticals , Inc. (OTC: ACUR ) announced a licensing, development and commercialization agreement with Abuse Deterrent Pharma – a special purpose company representing a consortium of investors, which will finance the company's operations and completion of the development of LTX-03 immediate-release tablets using Acura's patented LIMITx technology.
The investigational drug addresses the consequences of excess oral administration of opioid tablets, the most prevalent route of opioid overdose and abuse.
The transaction is valued up to $21.3 million, not including royalties. The agreement also provides for Acura receiving royalties and potential sales-related milestones and AD Pharma retaining commercialization rights.
COMPANY PROFILE
Acura Pharmaceuticals Inc is a specialty pharmaceutical company based in the US. It is engaged in the research, development, and commercialization of technologies and products intended to address medication abuse and misuse. The company has developed Aversion and Limitx technologies are intended to address methods of abuse associated with opioid analgesics whereas Impede technology is directed at minimizing the extraction and conversion of pseudoephedrine (PSE), into methamphetamine. Its product line includes OXAYDO which is a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and other pipeline products.
Green Growth Brands is well worth a risky long trade.
GREEN GROWTH BRANDS INC. (OTC) ($GGBXF)As a result of Peter Horvath, Green Growths CEO appearance on CNBC on Tuesday July 2nd, the volume and stock price had a incredible spike as he outlined the extent of their growth plans. Eight months ago the company had one shop. Now it has 60 and it's on track to have 240 in the next four months, Horvath explained.
The growth in the industry is incredible, and for Green Growth Brands, it wouldn't work without some help. The company has partnerships with Simon Property Group ( SPG ) and Brookfield Asset Management (BAM) . These two companies operate some of the best malls in the world, giving Green Growth Brands access to some of the best locations right away.
Abercrombie & Fitch (NYSE:ANF) and Green Growth Brands (OTCQB:GGBXF) plan to expand their partnership after testing Green Growth's Seventh Sense Botanical Therapy products in 10 A&F stores.
Abercrombie & Fitch will now carry the CBD products in more than 160 retail stores. The expansion includes Seventh Sense's CBD-infused body lotions, muscle balms, lip balms and sugar scrubs.
Source: Press Release
Green Growth Brands is well worth a risky long trade.
GREEN GROWTH BRANDS INC. (OTC) ($GGBXF)As a result of Peter Horvath, Green Growths CEO appearance on CNBC on Tuesday July 2nd, the volume and stock price had a incredible spike as he outlined the extent of their growth plans. Eight months ago the company had one shop. Now it has 60 and it's on track to have 240 in the next four months, Horvath explained.
The growth in the industry is incredible, and for Green Growth Brands, it wouldn't work without some help. The company has partnerships with Simon Property Group ( SPG ) and Brookfield Asset Management (BAM) . These two companies operate some of the best malls in the world, giving Green Growth Brands access to some of the best locations right away.
Abercrombie & Fitch (NYSE:ANF) and Green Growth Brands (OTCQB:GGBXF) plan to expand their partnership after testing Green Growth's Seventh Sense Botanical Therapy products in 10 A&F stores.
Abercrombie & Fitch will now carry the CBD products in more than 160 retail stores. The expansion includes Seventh Sense's CBD-infused body lotions, muscle balms, lip balms and sugar scrubs.
Source: Press Release
VOLUME HAS SPIKED IN ANTICIPATION OF POSITIVE CLINICAL DATA
CATALYST BIOSCIENCES INC CBOE ($CBIO)
CBIO will release at the ISTH conference final Phase 2 data for marzeptaacog alfa in hemophilia. Dr . Johnny Mahlangu, M.D., Professor of haematology, faculty of health sciences, head of the School of Pathology at the University of Witwatersrand in Johannesburg, South Africa, and a principal investigator on the MarzAA Phase 2 study, will deliver an oral presentation on the final data from the Company's next-generation engineered subcutaneous ( SQ ) coagulation Factor VIIa (FVIIa) marzeptacog alfa (activated) (MarzAA) Phase 2 trial for the treatment of hemophilia A or B with inhibitors. Additionally, the Company will have three posters covering (1) quality of life improvements for subjects in the Phase 2 MarzAA trial, (2) in silico and in vitro immunogenicity risk assessment of its next-generation engineered SQ coagulation Factor IX (FIX), dalcinonacog alfa (DalcA) compared with wildtype FIX and (3) the ongoing Phase 2b study of DalcA.
COMPANY PROFILE
COMPANY PROFILE
Catalyst Biosciences , Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address serious medical conditions. Its pipeline includes hemostasis such as Factor VIIa marzeptacog alfa, Factor IX dalcinonacog alfa, and Factor Xa; and anti-complement. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.
VOLUME HAS SPIKED IN ANTICIPATION OF POSITIVE CLINICAL DATA
CATALYST BIOSCIENCES INC CBOE ($CBIO)
CBIO will release at the ISTH conference final Phase 2 data for marzeptaacog alfa in hemophilia. Dr . Johnny Mahlangu, M.D., Professor of haematology, faculty of health sciences, head of the School of Pathology at the University of Witwatersrand in Johannesburg, South Africa, and a principal investigator on the MarzAA Phase 2 study, will deliver an oral presentation on the final data from the Company's next-generation engineered subcutaneous ( SQ ) coagulation Factor VIIa (FVIIa) marzeptacog alfa (activated) (MarzAA) Phase 2 trial for the treatment of hemophilia A or B with inhibitors. Additionally, the Company will have three posters covering (1) quality of life improvements for subjects in the Phase 2 MarzAA trial, (2) in silico and in vitro immunogenicity risk assessment of its next-generation engineered SQ coagulation Factor IX (FIX), dalcinonacog alfa (DalcA) compared with wildtype FIX and (3) the ongoing Phase 2b study of DalcA.
COMPANY PROFILE
COMPANY PROFILE
Catalyst Biosciences , Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address serious medical conditions. Its pipeline includes hemostasis such as Factor VIIa marzeptacog alfa, Factor IX dalcinonacog alfa, and Factor Xa; and anti-complement. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.
RLLVF could run +78% (or more) in share price today!
=====================
RLLVF (Relevium Technologies Inc.)
Alert Price: $0.06
Float: 122.64M
Website | Recent News
========================
The global nutraceutical market is estimated to be over $200 billion USD and is expected to reach $300 billion by the end of 2023.
Growing awareness regarding the consumption of healthy foods has resulted in increased demand for nutraceuticals in the U.S. The European market is driven by a steady innovation of high-performance natural ingredients used in nutraceuticals. Increasing adoption of e-commerce and growing consumer awareness through social media are further likely to augment the demand for nutraceuticals over the forecast period.
The market has witnessed an increased focus on the ingredients used for manufacturing nutraceuticals. The demand for natural products is expected to grow at a rapid pace over the next eight years as consumers perceive these products to be healthier and more effective as compared to synthetic products.
We have identified a rapidly growing micro-cap company that is already well positioned to capitalize on this multi-billion dollar market.
That company is Relevium Technologies, and it is publicly traded in three countries on three separate exchanges OTCQB: “RLLVF”, TSX.V: “RLV”, and Frankfurt: “6BX”.
About Relevium Technologies
Relevium Technologies operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operations of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products.
Relevium’s products are part of the $3.72 trillion dollar global wellness industry — one of the fastest growing worldwide markets. Their specific focus is on products that promote overall health, nutraceuticals, fitness nutrition and cosmeceuticals. The company already has 25 products being sold on Amazon with more being planned.
Relevium operates through two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including such as Walmart.com and Amazon.com.
The company’s product offering includes cutting-edge line of weight-loss, anti-inflammatory, heart, vision, beauty and fitness supplements sold through their Bioganix®, Push & Pull System® and LeefyLyfe® brands with the objective of helping people lose weight, become healthier, happier, and most importantly achieve the results that our customers desire.
Bioganix®, founded in 2014, has some of the best-selling products in the Health and Personal Care category on Amazon, and a loyal customer base. The combination of online marketing with an emphasis on superior quality products backed by stringent scientific research and formulations, this has developed Bioganix® in becoming one of the leading dietary supplement brands online.
Push & Pull®, launched in 2019, is the first comprehensive natural anti-aging system for complete skin care that combines Collagen Protein supplements (PUSH) and naturally sourced Aloe Vera skin anti-aging cream (PULL). This new brand targets a brand-new revenue stream in the burgeoning cosmeceutical market, which is the fastest growing segment of the health and wellness Market.
LeefyLyfe® is their OTC cannabidiol Phyto formulated brand that combines the same trusted ingredients as those found in Bioganix® and Push & Pull® with the benefits of CBD . The company is currently waiting for the decision by the FDA to allow the sale of CBD as a supplement in order to release its products into the market.
Since 2017, Relevium’s OTC has grown its product offering and expanded its distribution channels to some of the largest online marketplaces such as eBay , Amazon and Walmart.com. Relevium will continue to innovate with the BioGanix brand, expand the product line and distribution channels to further drive growth.
Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.
The company combines leading biopharma expertise, agricultural and logistic advantages of Colombia and trusted brand status with a clinically validation process for Phyto therapeutic medical products aimed at pediatric applications.
Biocannabix’ vertically integrated operations are located in key markets around the world: Canada, Colombia and Germany.
Scientific and Administrative Offices located in Montreal, Quebec
Cultivation and Extraction operations with an initial 20 hectares located in Cali , Colombia
Distribution and compliance partnership in Germany
The portfolio of Biocannabix brands include:
Cannakids®: Pediatric brand exclusive for the Canadian market
Relevium Senior®: Geriatric brand targeting inflammatory conditions including joints, heart and brain.
Relevium Kids®: Pediatric brand of Nutraceuticals and Oral Nutritional Supplements
Investment Highlights:
In 2017, the global wellness market reached $4.2T.
Global nutraceutical market to reach US$578.23B by 2025.
Vast distribution network through industry giants like Walmart and Amazon.
Building out 93,000-square-foot "Green Wave" cultivation and processing facility in Montreal, Quebec.
BioGanix generates approximately $1M in revenue per quarter.
47 SKUs developed for BioGanix to date.
Acquiring Cannakids’s IP , a leader in medical "Green Wave" patient research and pediatric and adult consumer product development.
Pending Sleipnir acquisition will initially bring in US$500K to Relevium’s topline revenue.
Partnership in place with HempCo Canada.
International expansion plans for all brands.
Recent Developments for Relevium
Relevium’s Biocannabix Positions Itself as an Important Player in Colombia as it Pursues Endo-Medical Cannabis Strategy for Latin America
Earlier this month, RLVRelevium’s Biocannabix positioned itself as an important player in the Colombian medical cannabis market by cementing medical and research relationships in the country in order to establish clinical validation programs for its Endo Nutraceutical Supplements (ENS) and Oral Nutritional Supplements.
On June 13th, 2019, the Company announced a binding LOI to acquire LifeLine Pharma SAS , a binding agreement to acquire the shares of Lifeline Pharma SAS , a Cali based cultivation and extraction business in the burgeoning agro-pharma market in Colombia. With a much lower cost of production, a robust commercial and legal framework and a culture that is open to Phyto therapeutic medicine, Colombia is quickly becoming a global center of medical cannabis supply and it is forecasted that the Country will be looking to supply as much as 44% of the World’s demand.
“This is a major strategic step in the development of our Phyto therapeutic biopharma business” stated Aurelio Useche, CEO of Relevium Technologies.
The Company’s subsidiary, Biocannabix Health Corporation, is a vertically integrated medical cannabis company with strategic positioning in three major markets: Canada, Latin America and Europe.
The company’s operations in Montreal allows Biocannabix to leverage leading edge scientific and research platforms as well as government incentives in the province of Quebec. The recent acquisition of LifeLine in Colombia allows the company to leverage lower costs of cultivation and processing as well as to manage its own genetics for the production of targeted Phyto therapeutic formulations. Colombia, Canada and Germany combined are central to the clinical validation program for the ENS and ONS products that will be offered in all three markets.
Relevium Takes Major Step in Latam to Acquire Lifeline Pharma in Cali , Colombia
Biocannabix Health Corporation (“Biocannabix”), a wholly-owned subsidiary of Relevium has executed on June 12, 2019 a binding agreement to acquire the shares of Lifeline Pharma SAS , a Cali based cultivation and extraction business in the burgeoning agro pharma market in Colombia.
KEY HIGHLIGHTS OF THE PARTNERSHIP WITH LIFELINE
Best in class partnership for international vertical integration.
Combination of Biocannabix focus on Pediatric Endo-Medicine with a large-scale operation with 150 years of sustainable, environmentally responsible and organic agricultural history
Located in Rozo, Valle del Cauca, in the heart of the sugar cane enclave seven minutes away from the international airport and 10 minutes away from Cali’s downtown core and a population of over 3M people
Multi-stage project with (1) an initial 5 hectares that includes the local offices, a laboratory, a fully enclosed greenhouse for tissue culture and micropropagation and an initial cultivation of over 200,000 square feet in open air green houses, (2) an option to expand to an additional 20 hectares or 2.2 million square feet of open air greenhouse cultivation and (3) the possibility to expand to another additional 60 hectares or 6.5 million square feet of cultivation.
Full registration of 668 genetic strains with the ICA , the Instituto Colombiano Agropecuario.
Three licenses in progress including (1) extraction and manufacturing, (2) cultivation with THC and (3) non-psychoactive cultivation, all with scientific research, domestic sales and export modalities.
Strategic low-cost infrastructure that allows for an estimated stage two flower capacity of 170,000 Kg per year with an initial estimated cost of production 0.53$ per gram.
Development of an industrial scale extraction plant in the Pacific Free Zone, a private industrial park located minutes away from the cultivation project. The free zone offers the benefits of the free regime and seeks to promote and develop the process of industrialization of goods, the productive chain and the provision of services, as well as strengthen the competitiveness of its users and customers by taking advantage of the generated opportunities from international trade and bilateral agreements signed by Colombia.
Genetics laboratory and agronomic research in the BioParque del Pacifico located in the campus of the International Center for Tropical Agriculture (CIAT) and the Colombian Corporation for agricultural research (Agrosavia).
STRATEGIC FIT FOR GLOBAL SUPPLY AND VERTICAL INTEGRATION
Relevium’s Bio-Pharma arm, Biocannabix, is focused in developing, marketing and selling endo-medicinal formulations on Nutraceuticals and Medical foods aimed primarily to pediatrics. An essential component of the strategy of delivering safe, 100% auditable medicine for pediatric patients is to ensure total control over the genetics, the cultivation and the processing of extracts. The partnership with Lifeline ensures a 100% organically grown product with access to over 600 registered genetic strains, the buildout of an EU GMP extraction facility in the Pacific Free Zone and the ability to trace and fully audit the process from seed to medicine through blockchain technology.
The strict regulation of the Colombian legal regime for cannabis only allow for the export of extracts and finished goods and we aim to service international demand for organically sourced medical cannabis extracts for LATAM, Europe and eventually the Asian continent.
LOCAL MARKET THAT IS READY TO ADOPT ENDO-MEDICINAL FORMULATIONS
Traditional remedies and natural medicine are an integral part of Colombian culture and with a fast-growing middle class and entrepreneurial nature, this market with a population of over 49 million is moving quickly to adopt cannabinoid therapy. Lifeline, through Biocannabix pediatric formulations, is poised to successfully obtain a significant market share of the local market.
TRANSACTION DETAILS
Under the terms of the binding agreement, Biocannabix will acquire 100% of the shares on Lifeline Pharma SAS by investing an initial US$850,000 to be deployed during stage one of the projects. The initial investment is comprised of US$125,000 at signing, US$125,000 upon the grant of the initial licenses and a commitment to deploy funds totalling US$600,000 over the next seven months. As part of the transaction, Biocannabix Health Corporation will issue US$3,650,000 in shares representing approximately 41% of the shares outstanding of the wholly owned subsidiary.
In the event of a major transaction including a sale or a public offering, the shareholders of Lifeline Pharma will also receive an additional US$1.5 million to be settled in shares of Biocannabix or in cash.
Aurelio Useche, CEO of Relevium stated: “The acquisition and partnership with Lifeline Pharma SAS in Colombia represents the single most important development to date for Relevium, our team and our shareholders. This is the culmination of months of strategic re-alignment, negotiations and a lot of hard work by our team and the key stakeholders of Lifeline”. Mr. Useche added:” We are very pleased and proud to partner with the amazing team of Lifeline, including Oscar LIbreros CEO and Hossein Shadanlou COO and look forward to work together to execute on the common mission of providing safe, organically sourced and fully auditable endo-medicinal products for pediatric applications”
Oscar LIbreros, CEO of Lifeline Pharma SAS stated: “With over 150 years of tradition in organic farming and our objective to provide the best medical cannabis extracts and products, we are happy (THRILLED) to join forces and merge with Biocannabix Health Corporation in Canada. We look forward to delivering real value through the disciplined deployment of our operational strategy from Colombia to the world”
Cannabis Cultivation and Extraction Potentially Costs 80% Less in Latin America
With a much lower cost of production, a robust commercial and legal framework and a culture that is open to Phyto therapeutic medicine, Colombia is quickly becoming a global center of medical cannabis supply and it is forecasted that the Country will be looking to supply as much as 44% of the World's demand.
The region boasts exceptional climatic conditions, with lots of sunshine and good rainfall. This coupled with acres and acres of arable land, could make the LATAM region the global leaders in cannabis production.
In addition to the above, the price of labor is exceptionally cheap when compared to it's European and North American counterparts. Combined, it is estimated that LATAM will be able to produce cannabis – in commercial quantities – for nearly 80% less than the rest of the world. That's a pretty big advantage.
The recent acquisition of LifeLine in Colombia allows the company to leverage lower costs of cultivation and processing as well as to manage its own genetics for the production of targeted Phyto therapeutic formulations. Colombia, Canada and Germany combined are central to the clinical validation program for the ENS and ONS products that will be offered in all three markets.
We See the Potential For a +78% Move From Here
We've done our very own chart analysis, and we see the potential for a move of +78% from here.
Bullish Technical Indicators:
Well defined price channel established with respected trendlines .
Bottom hit and reversed on the daily candle.
Accumulative volume spikes.
Bounce off well defined trendline . Ready to trend higher.
Increased volume .
The Bottom Line
RLLVF deserves your immediate attention
We suggest that you add this rapidly growing micro-cap to the top of your watch-list, as these triggered technical indicators and company news could bring serious interest to this stock.
Best Regards,
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated three thousand dollars by STM LLC for an investor relations advertising marketing campaign w/ 2000 TradingView™ views for RLLVF. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
RLLVF could run +78% (or more) in share price today!
=====================
RLLVF (Relevium Technologies Inc.)
Alert Price: $0.06
Float: 122.64M
Website | Recent News
========================
The global nutraceutical market is estimated to be over $200 billion USD and is expected to reach $300 billion by the end of 2023.
Growing awareness regarding the consumption of healthy foods has resulted in increased demand for nutraceuticals in the U.S. The European market is driven by a steady innovation of high-performance natural ingredients used in nutraceuticals. Increasing adoption of e-commerce and growing consumer awareness through social media are further likely to augment the demand for nutraceuticals over the forecast period.
The market has witnessed an increased focus on the ingredients used for manufacturing nutraceuticals. The demand for natural products is expected to grow at a rapid pace over the next eight years as consumers perceive these products to be healthier and more effective as compared to synthetic products.
We have identified a rapidly growing micro-cap company that is already well positioned to capitalize on this multi-billion dollar market.
That company is Relevium Technologies, and it is publicly traded in three countries on three separate exchanges OTCQB: “RLLVF”, TSX.V: “RLV”, and Frankfurt: “6BX”.
About Relevium Technologies
Relevium Technologies operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operations of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products.
Relevium’s products are part of the $3.72 trillion dollar global wellness industry — one of the fastest growing worldwide markets. Their specific focus is on products that promote overall health, nutraceuticals, fitness nutrition and cosmeceuticals. The company already has 25 products being sold on Amazon with more being planned.
Relevium operates through two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including such as Walmart.com and Amazon.com.
The company’s product offering includes cutting-edge line of weight-loss, anti-inflammatory, heart, vision, beauty and fitness supplements sold through their Bioganix®, Push & Pull System® and LeefyLyfe® brands with the objective of helping people lose weight, become healthier, happier, and most importantly achieve the results that our customers desire.
Bioganix®, founded in 2014, has some of the best-selling products in the Health and Personal Care category on Amazon, and a loyal customer base. The combination of online marketing with an emphasis on superior quality products backed by stringent scientific research and formulations, this has developed Bioganix® in becoming one of the leading dietary supplement brands online.
Push & Pull®, launched in 2019, is the first comprehensive natural anti-aging system for complete skin care that combines Collagen Protein supplements (PUSH) and naturally sourced Aloe Vera skin anti-aging cream (PULL). This new brand targets a brand-new revenue stream in the burgeoning cosmeceutical market, which is the fastest growing segment of the health and wellness Market.
LeefyLyfe® is their OTC cannabidiol Phyto formulated brand that combines the same trusted ingredients as those found in Bioganix® and Push & Pull® with the benefits of CBD . The company is currently waiting for the decision by the FDA to allow the sale of CBD as a supplement in order to release its products into the market.
Since 2017, Relevium’s OTC has grown its product offering and expanded its distribution channels to some of the largest online marketplaces such as eBay , Amazon and Walmart.com. Relevium will continue to innovate with the BioGanix brand, expand the product line and distribution channels to further drive growth.
Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.
The company combines leading biopharma expertise, agricultural and logistic advantages of Colombia and trusted brand status with a clinically validation process for Phyto therapeutic medical products aimed at pediatric applications.
Biocannabix’ vertically integrated operations are located in key markets around the world: Canada, Colombia and Germany.
Scientific and Administrative Offices located in Montreal, Quebec
Cultivation and Extraction operations with an initial 20 hectares located in Cali , Colombia
Distribution and compliance partnership in Germany
The portfolio of Biocannabix brands include:
Cannakids®: Pediatric brand exclusive for the Canadian market
Relevium Senior®: Geriatric brand targeting inflammatory conditions including joints, heart and brain.
Relevium Kids®: Pediatric brand of Nutraceuticals and Oral Nutritional Supplements
Investment Highlights:
In 2017, the global wellness market reached $4.2T.
Global nutraceutical market to reach US$578.23B by 2025.
Vast distribution network through industry giants like Walmart and Amazon.
Building out 93,000-square-foot "Green Wave" cultivation and processing facility in Montreal, Quebec.
BioGanix generates approximately $1M in revenue per quarter.
47 SKUs developed for BioGanix to date.
Acquiring Cannakids’s IP , a leader in medical "Green Wave" patient research and pediatric and adult consumer product development.
Pending Sleipnir acquisition will initially bring in US$500K to Relevium’s topline revenue.
Partnership in place with HempCo Canada.
International expansion plans for all brands.
Recent Developments for Relevium
Relevium’s Biocannabix Positions Itself as an Important Player in Colombia as it Pursues Endo-Medical Cannabis Strategy for Latin America
Earlier this month, RLVRelevium’s Biocannabix positioned itself as an important player in the Colombian medical cannabis market by cementing medical and research relationships in the country in order to establish clinical validation programs for its Endo Nutraceutical Supplements (ENS) and Oral Nutritional Supplements.
On June 13th, 2019, the Company announced a binding LOI to acquire LifeLine Pharma SAS , a binding agreement to acquire the shares of Lifeline Pharma SAS , a Cali based cultivation and extraction business in the burgeoning agro-pharma market in Colombia. With a much lower cost of production, a robust commercial and legal framework and a culture that is open to Phyto therapeutic medicine, Colombia is quickly becoming a global center of medical cannabis supply and it is forecasted that the Country will be looking to supply as much as 44% of the World’s demand.
“This is a major strategic step in the development of our Phyto therapeutic biopharma business” stated Aurelio Useche, CEO of Relevium Technologies.
The Company’s subsidiary, Biocannabix Health Corporation, is a vertically integrated medical cannabis company with strategic positioning in three major markets: Canada, Latin America and Europe.
The company’s operations in Montreal allows Biocannabix to leverage leading edge scientific and research platforms as well as government incentives in the province of Quebec. The recent acquisition of LifeLine in Colombia allows the company to leverage lower costs of cultivation and processing as well as to manage its own genetics for the production of targeted Phyto therapeutic formulations. Colombia, Canada and Germany combined are central to the clinical validation program for the ENS and ONS products that will be offered in all three markets.
Relevium Takes Major Step in Latam to Acquire Lifeline Pharma in Cali , Colombia
Biocannabix Health Corporation (“Biocannabix”), a wholly-owned subsidiary of Relevium has executed on June 12, 2019 a binding agreement to acquire the shares of Lifeline Pharma SAS , a Cali based cultivation and extraction business in the burgeoning agro pharma market in Colombia.
KEY HIGHLIGHTS OF THE PARTNERSHIP WITH LIFELINE
Best in class partnership for international vertical integration.
Combination of Biocannabix focus on Pediatric Endo-Medicine with a large-scale operation with 150 years of sustainable, environmentally responsible and organic agricultural history
Located in Rozo, Valle del Cauca, in the heart of the sugar cane enclave seven minutes away from the international airport and 10 minutes away from Cali’s downtown core and a population of over 3M people
Multi-stage project with (1) an initial 5 hectares that includes the local offices, a laboratory, a fully enclosed greenhouse for tissue culture and micropropagation and an initial cultivation of over 200,000 square feet in open air green houses, (2) an option to expand to an additional 20 hectares or 2.2 million square feet of open air greenhouse cultivation and (3) the possibility to expand to another additional 60 hectares or 6.5 million square feet of cultivation.
Full registration of 668 genetic strains with the ICA , the Instituto Colombiano Agropecuario.
Three licenses in progress including (1) extraction and manufacturing, (2) cultivation with THC and (3) non-psychoactive cultivation, all with scientific research, domestic sales and export modalities.
Strategic low-cost infrastructure that allows for an estimated stage two flower capacity of 170,000 Kg per year with an initial estimated cost of production 0.53$ per gram.
Development of an industrial scale extraction plant in the Pacific Free Zone, a private industrial park located minutes away from the cultivation project. The free zone offers the benefits of the free regime and seeks to promote and develop the process of industrialization of goods, the productive chain and the provision of services, as well as strengthen the competitiveness of its users and customers by taking advantage of the generated opportunities from international trade and bilateral agreements signed by Colombia.
Genetics laboratory and agronomic research in the BioParque del Pacifico located in the campus of the International Center for Tropical Agriculture (CIAT) and the Colombian Corporation for agricultural research (Agrosavia).
STRATEGIC FIT FOR GLOBAL SUPPLY AND VERTICAL INTEGRATION
Relevium’s Bio-Pharma arm, Biocannabix, is focused in developing, marketing and selling endo-medicinal formulations on Nutraceuticals and Medical foods aimed primarily to pediatrics. An essential component of the strategy of delivering safe, 100% auditable medicine for pediatric patients is to ensure total control over the genetics, the cultivation and the processing of extracts. The partnership with Lifeline ensures a 100% organically grown product with access to over 600 registered genetic strains, the buildout of an EU GMP extraction facility in the Pacific Free Zone and the ability to trace and fully audit the process from seed to medicine through blockchain technology.
The strict regulation of the Colombian legal regime for cannabis only allow for the export of extracts and finished goods and we aim to service international demand for organically sourced medical cannabis extracts for LATAM, Europe and eventually the Asian continent.
LOCAL MARKET THAT IS READY TO ADOPT ENDO-MEDICINAL FORMULATIONS
Traditional remedies and natural medicine are an integral part of Colombian culture and with a fast-growing middle class and entrepreneurial nature, this market with a population of over 49 million is moving quickly to adopt cannabinoid therapy. Lifeline, through Biocannabix pediatric formulations, is poised to successfully obtain a significant market share of the local market.
TRANSACTION DETAILS
Under the terms of the binding agreement, Biocannabix will acquire 100% of the shares on Lifeline Pharma SAS by investing an initial US$850,000 to be deployed during stage one of the projects. The initial investment is comprised of US$125,000 at signing, US$125,000 upon the grant of the initial licenses and a commitment to deploy funds totalling US$600,000 over the next seven months. As part of the transaction, Biocannabix Health Corporation will issue US$3,650,000 in shares representing approximately 41% of the shares outstanding of the wholly owned subsidiary.
In the event of a major transaction including a sale or a public offering, the shareholders of Lifeline Pharma will also receive an additional US$1.5 million to be settled in shares of Biocannabix or in cash.
Aurelio Useche, CEO of Relevium stated: “The acquisition and partnership with Lifeline Pharma SAS in Colombia represents the single most important development to date for Relevium, our team and our shareholders. This is the culmination of months of strategic re-alignment, negotiations and a lot of hard work by our team and the key stakeholders of Lifeline”. Mr. Useche added:” We are very pleased and proud to partner with the amazing team of Lifeline, including Oscar LIbreros CEO and Hossein Shadanlou COO and look forward to work together to execute on the common mission of providing safe, organically sourced and fully auditable endo-medicinal products for pediatric applications”
Oscar LIbreros, CEO of Lifeline Pharma SAS stated: “With over 150 years of tradition in organic farming and our objective to provide the best medical cannabis extracts and products, we are happy (THRILLED) to join forces and merge with Biocannabix Health Corporation in Canada. We look forward to delivering real value through the disciplined deployment of our operational strategy from Colombia to the world”
Cannabis Cultivation and Extraction Potentially Costs 80% Less in Latin America
With a much lower cost of production, a robust commercial and legal framework and a culture that is open to Phyto therapeutic medicine, Colombia is quickly becoming a global center of medical cannabis supply and it is forecasted that the Country will be looking to supply as much as 44% of the World's demand.
The region boasts exceptional climatic conditions, with lots of sunshine and good rainfall. This coupled with acres and acres of arable land, could make the LATAM region the global leaders in cannabis production.
In addition to the above, the price of labor is exceptionally cheap when compared to it's European and North American counterparts. Combined, it is estimated that LATAM will be able to produce cannabis – in commercial quantities – for nearly 80% less than the rest of the world. That's a pretty big advantage.
The recent acquisition of LifeLine in Colombia allows the company to leverage lower costs of cultivation and processing as well as to manage its own genetics for the production of targeted Phyto therapeutic formulations. Colombia, Canada and Germany combined are central to the clinical validation program for the ENS and ONS products that will be offered in all three markets.
We See the Potential For a +78% Move From Here
We've done our very own chart analysis, and we see the potential for a move of +78% from here.
Bullish Technical Indicators:
Well defined price channel established with respected trendlines .
Bottom hit and reversed on the daily candle.
Accumulative volume spikes.
Bounce off well defined trendline . Ready to trend higher.
Increased volume .
The Bottom Line
RLLVF deserves your immediate attention
We suggest that you add this rapidly growing micro-cap to the top of your watch-list, as these triggered technical indicators and company news could bring serious interest to this stock.
Best Regards,
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated three thousand dollars by STM LLC for an investor relations advertising marketing campaign w/ 2000 TradingView™ views for RLLVF. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Bullish trade setup in Charlottes Web Holdings Inc.
After a deep correction CWBHF has made a fantastic reversal, and is showing very bullish momentum, having missed the initial move now is not the time to be entering a long trade. Our next set up is to long on a break above the .65FIB and the upper Ichimoku Cloud , it may mean missing some gains but a favourable market will still yield a 20% return prior to reaching ATH .
Bullish trade setup in Charlottes Web Holdings Inc.
After a deep correction CWBHF has made a fantastic reversal, and is showing very bullish momentum, having missed the initial move now is not the time to be entering a long trade. Our next set up is to long on a break above the .65FIB and the upper Ichimoku Cloud , it may mean missing some gains but a favourable market will still yield a 20% return prior to reaching ATH .
IMTL is our new low float subpenny alert.New Partnership w/KODAK
========================
IMTL (Image Protect Inc.)
Alert Price: $0.0042
Float: 134M
Chart Analysis
Corporate Video
Investor Presentation
CEO Interview
Website | Recent News
========================
Members,
We're kicking off this fresh week of trading with an exciting subpenny alert with triple-digit gain potential.
Please turn your immediate attention to IMTL (Image Protect Inc.).
As many of you know already, we love these low-float, subpenny picks, because even the slightest move in share price can result in monster gains for traders.
Our latest alert IMTL , is showing us all the signs of a company that could breakout for monster gains in a very short amount of time.
On Tuesday, IMTL dropped huge news that we believe the market hasn't had a chance to react to yet.
The Company announced the formation and signing of a strategic partnership agreement (the “Partnership”) with RYDE Holding (“RYDE”), the creator and operator of the KODAKOne Image Rights Management Platform.
The two companies believe the Partnership will generate over $5 million in digital image copyright infringement claims and drive tangible revenue growth starting in calendar Q3 2019.
This is the type of news that could send shares of this low-float, subpenny alert soaring in no time at all!
The Bullish Case for IMTL
This global leader in the end-to-end copyright infringement sector has/is:
Just $1.2M worth of shares available for trading, so you can expect a huge move from it on tomorrow's anticipated jump in share volume .
Operating in a rapidly growing image ad market expected by notable analysts to reach $400 Billion by 2025.
On schedule to launch Fotofy on August 1st, Fotofy is the Industry’s only Image Market Place, where-in Users and Rightsholders get paid through a streamlined In-Image Marketing program.
Trading on a bottom'd out chart, near its 52-week low (Major Bounce Opportunity)
Upside of over +733%!
We don't think IMTL is going to be a subpenny stock for much longer.
In fact, if IMTL were to rally back to $0.01, traders would see gains of over +138%!
In our opinion, the upside for IMTL is just too good to ignore.
That being said,we ask that you start your research now, and consider building a position in IMTL tomorrow morning at 9:30AM EST!
About Image Protect Inc.
Image Protect Inc. (OTC: IMTL ) (imageprotect.com) protects and monetizes creative works. By uniting technology with a team of copyright experts, they ensure that content providers preserve the value of their digital assets. Their web application monitors the global Internet to seek and collect evidence for illegally used visual content. Then their legal partners across North America, Europe, and Asia ensure their clients receive appropriate compensation for work used without valid license.
IMTL By the Numbers:
30 Media Agencies Onboard
300K Independent Photographers
4.5M Images Currently Monitored
20+ International IP Legal Partners
Revenue Model
Subscription-based model for individual photographers
End-to-end tracking and recovery model for individual photographers and large media agencies
Subscription tracking only model for photo agencies ad brands
Copyright registration model
IMTL is Ready to Change the Photo Industry with Fotofy
The evolution of Fotofy technology brings the Company to the threshold of an entirely new and disruptive approach to the Photo industry. IMTL will unveil the Industry’s only Image Market Place, where-in Users and Rightsholders get paid through a streamlined In-Image Marketing program. This uniquely positions management to further capitalize by moving into this rapidly growing market expected by notable analysts to reach $400 Billion by 2025.
Click here to see how Fotofy is going to change the photo industry forever
The Fotofy launch is on schedule, and is set to go live on August 1!
The news of this upcoming product launch has us extremely bullish on IMTL .
Image Protect Partners with MadHive To Monetize IPShare™ in $105B Ad-Tech Space
IMTL formed a strategic partnership with MadHive (madhive.com), a leading blockchain-driven data management platform in the ad-tech marketplace that served over 3 billion ad impressions in 2018. The partnership is predicated on the objective of exploring, defining, and deploying a monetization strategy for the Company’s powerful IPShare™ technology as a programmatic digital advertising model.
“We believe the future of technology is decentralized,” said Adam Helfgott, CEO of MadHive. “We are building the 'pipes' for a decentralized ad network, and Image Protect is building something special within our network.”
According to recent MAGNA Group research, the advertising industry hit a record $552 billion in global sales in 2018, which represents an increase of 7.2% on a year-over-year basis. Digital advertising accounts for 35% of the overall market. But consumer research suggests this share could increase dramatically over coming years, with blockchain technology representing a powerful avenue for this transition. According to research from Zenith, “Digital is driving virtually all growth in the global ad market.”
Management notes that MadHive has a proven track record in leveraging blockchain technology for the authentication of “true value transactions” in the ad-tech ecosystem without sacrificing either transparency or efficiency. The Company believes that this will help to establish a clear path to monetizing the IPShare™ model given the accuracy and exchange efficiency of both ad impressions and data analytics within the MadHive platform.
“We are currently testing 2.5 million images, including the monetization of dormant images,” noted Matthew Goldman, Image Protect CO-CEO. “Once testing has been completed, MadHive will collaborate with digital advertising agencies to utilize these images as digital billboards.”
Management believes that its IPShare™ model will deliver an empowering AD-Technology solution to mainstream digital image rightsholders and content creators, leveraging the power of to manage digital licenses, in-photo advertisements, and revolutionary user analytics for tracking, protecting, and monetizing the digital life of proprietary content.
Encouraging rightsholders to join the Image Protect platform has been easier than ever – which is exciting, because it means the past four years of hard work is finally starting to pay off . “IPShare™ is changing the way people can market online. Pictures converted to the IPShare™ format can be embedded with advertisements – think YouTube and Facebook ads, but in picture format. Content owners immediately see the value and are thrilled to become a part of the Image Protect team.”
ICOx Innovations Client RYDE Holding Inc. Signs Partnership Agreement With Image Protect That Is Expected to Generate a Significant Amount in Infringement Claims
The partnership will integrate Image Protect’s License Recovery Unit with RYDE Holding’s KODAKOne platform which will add thousands of new copyright infringement cases and numerous new digital rights holder clients to the KODAKOne platform. Additionally, this integration will generate a significant amount in infringement claims starting within the next two months.
"This is very exciting news for ICOx Innovations’ client RYDE Holding Inc. This collaboration will result in increases across the board in use cases, new clients and revenues, in addition to extending global services. This is the first in many great partnerships.” noted ICOx Innovations President, Bruce Elliott .
Jan Denecke, CEO of RYDE Holding said “We are very excited about our partnership with Image Protect. Together, we will continue to help protect digital storytellers worldwide. Additional cases provided by Image Protect ultimately compliment and fortify our presence in North America, Europe and SE Asia.”
Matthew Goldman, CEO Image Protect noted, “Through KODAKOne’s global post-licensing service we now extend our service offer to our clients by additionally recovering licenses from new markets such as Europe and SE Asia. This integration provides an opportunity for both the companies to generate and share untapped image infringement claims that will benefit both the companies by generating significant additional revenues.”
The RYDE and Image Protect partnership will be implemented over the coming quarter, with infringement identification, fee collections and revenues targeted to commence in August 2019.
Recent Developments:
Image Protect Partners with KODAKOne in Deal Expected to Generate Over $5M in Digital Image Rights Revenues
Last Wednesday, IMTL announced the formation and signing of a strategic partnership agreement (the “Partnership”) with RYDE Holding (“RYDE”), the creator and operator of the KODAKOne Image Rights Management Platform.
The two companies believe the Partnership will generate over $5 million in digital image copyright infringement claims and drive tangible revenue growth starting in calendar Q3 2019.
A Media Snippet accompanying this announcement is available by clicking on the image or link below:
Image Protect Snippet: Image Protect Partners with KODAKOne in Deal Expected to Generate Over $5M in Digital Image Rights Revenues
Matthew Goldmann, CEO Image Protect noted, "Through KODAKOne’s global post-licensing service we now extend our service offer to our clients by additionally recovering licenses from new markets such as Europe and SE Asia. This integration provides an opportunity to generate and share untapped image infringement claims that will benefit both companies by generating significant additional revenues. This will enable Image Protect to continue to scale at unprecedented rates."
The partnership will integrate Image Protect's License Recovery Unit with RYDE Holding's KODAKOne platform, creating an overlap that will bring the KODAKOne platform to bear on thousands of new copyright infringement cases and numerous new digital rightsholder clients.
The two companies believe that this integration will position the Partnership in a market-leading role in the digital image rights protection space as the overall cloud-based digital rights management market continues to grow from $491.5 million in 2016 to just over $2.5 billion by 2025 (according to a ResearchNReports study).
RYDE CEO , Jan Denecke, said, "We are very excited about our partnership with Image Protect. Together, we will continue to help protect digital storytellers worldwide. Additional cases provided by Image Protect ultimately compliment and fortify our presence in North America, Europe and SE Asia.”
The Partnership will be implemented over the coming quarter, with infringement identification, settlements, and revenues targeted to commence immediately.
Market Outlook:
CNBC Report Reveals Digital Ad Revenue Experienced 21.8% Boost in 2018, Eclipsing 2017 Revenues of $88.3 Billion
According to a CNBC.com report, digital ad growth has bolstered over $100 Billion from advertisers seeking massive audiences and targeting tech giants like Google and Facebook .
“The momentum behind this paradigm shift represents a tremendous opportunity for our Company, Rightsholders, and shareholders,” stated Matthew Goldman, Image Protect Co-CEO. “It’s not often when timing and opportunity meet simultaneously. In consideration of our launch in the industry, we firmly believe that the window of opportunity is now.” He concluded: “Standing on the threshold of a revolutionized industry, we view our growth potential to be considerably higher than we’ve ever experienced with the Copyright model.”
The new report states internet advertising revenues in the U.S. totaled $107.5 billion for full-year 2018 — the first time that figure has topped $100 billion. The report, commissioned by the Interactive Advertising Bureau ( IAB ) and conducted by PwC, said revenue in 2018 was 21.8% higher than full-year 2017 revenue of $88.3 billion. That double-digit growth in internet advertising comes as TV advertising increased 1.4% and radio grew 1% from 2017 to 2018, according to the report. Meanwhile, newspaper advertising decreased 6.9% and magazine advertising fell 2.1% in 2018 year over year.
An in-depth research report released last month forecasted the global growth of the native advertising market to 2025. Analysis of overall digital ad spend growth, combined with native advertising trends per market, globally, has revealed that native advertising spend is expected to increase by 372% from 2020 to 2025.
This represents an increase in the native advertising market from $85.83Bn in 2020 to a total global value of $402Bn by 2025. Image Protect stands uniquely positioned to immerse itself into this growing Industry by way of its extensive experience in the Photo Industry.
Technical Analysis:
We love these low-float, subpenny picks, because even the slightest move in share price can result in monster gains for traders.
IMTL has a well recorded history of showing traders some highly profitable intraday swings.
It is also trading just slightly above its 52-week low, which leads us to believe that its upside potential far outweighs its downside risk.
In fact, a run back to its 52-week high of $0.035 from today's alert price would net traders over +733% in pure profit!
We've done our very own chart analysis, and see the potential for a move of +161%!
The Bottom Line
As we stated above, we don't think IMTL is going to be a subpenny stock for much longer.
The Company is operating in a multi-billion dollar sector, and is set to launch game changing technology in just a few weeks on August 1st.
This could be one of your last chances to grab up shares for under a penny.
That being said, we ask that all members start their research on IMTL immediately, and consider building a position tomorrow morning at 9:30AM EST
(*Remember to use a Basic Stop-Loss Order or more advanced Stop Limit Order to protect your gains, as well as limit possible losses.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by ACN LLC for a 1-day investor relations advertising marketing campaign w/ 1000 TradingView™ views for IMTL . We have been previously compensated ten thousand dollars by ACN LLC to conduct investor relations advertising and marketing for IMTL-which has expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
IMTL is our new low float subpenny alert.New Partnership w/KODAK
========================
IMTL (Image Protect Inc.)
Alert Price: $0.0042
Float: 134M
Chart Analysis
Corporate Video
Investor Presentation
CEO Interview
Website | Recent News
========================
Members,
We're kicking off this fresh week of trading with an exciting subpenny alert with triple-digit gain potential.
Please turn your immediate attention to IMTL (Image Protect Inc.).
As many of you know already, we love these low-float, subpenny picks, because even the slightest move in share price can result in monster gains for traders.
Our latest alert IMTL , is showing us all the signs of a company that could breakout for monster gains in a very short amount of time.
On Tuesday, IMTL dropped huge news that we believe the market hasn't had a chance to react to yet.
The Company announced the formation and signing of a strategic partnership agreement (the “Partnership”) with RYDE Holding (“RYDE”), the creator and operator of the KODAKOne Image Rights Management Platform.
The two companies believe the Partnership will generate over $5 million in digital image copyright infringement claims and drive tangible revenue growth starting in calendar Q3 2019.
This is the type of news that could send shares of this low-float, subpenny alert soaring in no time at all!
The Bullish Case for IMTL
This global leader in the end-to-end copyright infringement sector has/is:
Just $1.2M worth of shares available for trading, so you can expect a huge move from it on tomorrow's anticipated jump in share volume .
Operating in a rapidly growing image ad market expected by notable analysts to reach $400 Billion by 2025.
On schedule to launch Fotofy on August 1st, Fotofy is the Industry’s only Image Market Place, where-in Users and Rightsholders get paid through a streamlined In-Image Marketing program.
Trading on a bottom'd out chart, near its 52-week low (Major Bounce Opportunity)
Upside of over +733%!
We don't think IMTL is going to be a subpenny stock for much longer.
In fact, if IMTL were to rally back to $0.01, traders would see gains of over +138%!
In our opinion, the upside for IMTL is just too good to ignore.
That being said,we ask that you start your research now, and consider building a position in IMTL tomorrow morning at 9:30AM EST!
About Image Protect Inc.
Image Protect Inc. (OTC: IMTL ) (imageprotect.com) protects and monetizes creative works. By uniting technology with a team of copyright experts, they ensure that content providers preserve the value of their digital assets. Their web application monitors the global Internet to seek and collect evidence for illegally used visual content. Then their legal partners across North America, Europe, and Asia ensure their clients receive appropriate compensation for work used without valid license.
IMTL By the Numbers:
30 Media Agencies Onboard
300K Independent Photographers
4.5M Images Currently Monitored
20+ International IP Legal Partners
Revenue Model
Subscription-based model for individual photographers
End-to-end tracking and recovery model for individual photographers and large media agencies
Subscription tracking only model for photo agencies ad brands
Copyright registration model
IMTL is Ready to Change the Photo Industry with Fotofy
The evolution of Fotofy technology brings the Company to the threshold of an entirely new and disruptive approach to the Photo industry. IMTL will unveil the Industry’s only Image Market Place, where-in Users and Rightsholders get paid through a streamlined In-Image Marketing program. This uniquely positions management to further capitalize by moving into this rapidly growing market expected by notable analysts to reach $400 Billion by 2025.
Click here to see how Fotofy is going to change the photo industry forever
The Fotofy launch is on schedule, and is set to go live on August 1!
The news of this upcoming product launch has us extremely bullish on IMTL .
Image Protect Partners with MadHive To Monetize IPShare™ in $105B Ad-Tech Space
IMTL formed a strategic partnership with MadHive (madhive.com), a leading blockchain-driven data management platform in the ad-tech marketplace that served over 3 billion ad impressions in 2018. The partnership is predicated on the objective of exploring, defining, and deploying a monetization strategy for the Company’s powerful IPShare™ technology as a programmatic digital advertising model.
“We believe the future of technology is decentralized,” said Adam Helfgott, CEO of MadHive. “We are building the 'pipes' for a decentralized ad network, and Image Protect is building something special within our network.”
According to recent MAGNA Group research, the advertising industry hit a record $552 billion in global sales in 2018, which represents an increase of 7.2% on a year-over-year basis. Digital advertising accounts for 35% of the overall market. But consumer research suggests this share could increase dramatically over coming years, with blockchain technology representing a powerful avenue for this transition. According to research from Zenith, “Digital is driving virtually all growth in the global ad market.”
Management notes that MadHive has a proven track record in leveraging blockchain technology for the authentication of “true value transactions” in the ad-tech ecosystem without sacrificing either transparency or efficiency. The Company believes that this will help to establish a clear path to monetizing the IPShare™ model given the accuracy and exchange efficiency of both ad impressions and data analytics within the MadHive platform.
“We are currently testing 2.5 million images, including the monetization of dormant images,” noted Matthew Goldman, Image Protect CO-CEO. “Once testing has been completed, MadHive will collaborate with digital advertising agencies to utilize these images as digital billboards.”
Management believes that its IPShare™ model will deliver an empowering AD-Technology solution to mainstream digital image rightsholders and content creators, leveraging the power of to manage digital licenses, in-photo advertisements, and revolutionary user analytics for tracking, protecting, and monetizing the digital life of proprietary content.
Encouraging rightsholders to join the Image Protect platform has been easier than ever – which is exciting, because it means the past four years of hard work is finally starting to pay off . “IPShare™ is changing the way people can market online. Pictures converted to the IPShare™ format can be embedded with advertisements – think YouTube and Facebook ads, but in picture format. Content owners immediately see the value and are thrilled to become a part of the Image Protect team.”
ICOx Innovations Client RYDE Holding Inc. Signs Partnership Agreement With Image Protect That Is Expected to Generate a Significant Amount in Infringement Claims
The partnership will integrate Image Protect’s License Recovery Unit with RYDE Holding’s KODAKOne platform which will add thousands of new copyright infringement cases and numerous new digital rights holder clients to the KODAKOne platform. Additionally, this integration will generate a significant amount in infringement claims starting within the next two months.
"This is very exciting news for ICOx Innovations’ client RYDE Holding Inc. This collaboration will result in increases across the board in use cases, new clients and revenues, in addition to extending global services. This is the first in many great partnerships.” noted ICOx Innovations President, Bruce Elliott .
Jan Denecke, CEO of RYDE Holding said “We are very excited about our partnership with Image Protect. Together, we will continue to help protect digital storytellers worldwide. Additional cases provided by Image Protect ultimately compliment and fortify our presence in North America, Europe and SE Asia.”
Matthew Goldman, CEO Image Protect noted, “Through KODAKOne’s global post-licensing service we now extend our service offer to our clients by additionally recovering licenses from new markets such as Europe and SE Asia. This integration provides an opportunity for both the companies to generate and share untapped image infringement claims that will benefit both the companies by generating significant additional revenues.”
The RYDE and Image Protect partnership will be implemented over the coming quarter, with infringement identification, fee collections and revenues targeted to commence in August 2019.
Recent Developments:
Image Protect Partners with KODAKOne in Deal Expected to Generate Over $5M in Digital Image Rights Revenues
Last Wednesday, IMTL announced the formation and signing of a strategic partnership agreement (the “Partnership”) with RYDE Holding (“RYDE”), the creator and operator of the KODAKOne Image Rights Management Platform.
The two companies believe the Partnership will generate over $5 million in digital image copyright infringement claims and drive tangible revenue growth starting in calendar Q3 2019.
A Media Snippet accompanying this announcement is available by clicking on the image or link below:
Image Protect Snippet: Image Protect Partners with KODAKOne in Deal Expected to Generate Over $5M in Digital Image Rights Revenues
Matthew Goldmann, CEO Image Protect noted, "Through KODAKOne’s global post-licensing service we now extend our service offer to our clients by additionally recovering licenses from new markets such as Europe and SE Asia. This integration provides an opportunity to generate and share untapped image infringement claims that will benefit both companies by generating significant additional revenues. This will enable Image Protect to continue to scale at unprecedented rates."
The partnership will integrate Image Protect's License Recovery Unit with RYDE Holding's KODAKOne platform, creating an overlap that will bring the KODAKOne platform to bear on thousands of new copyright infringement cases and numerous new digital rightsholder clients.
The two companies believe that this integration will position the Partnership in a market-leading role in the digital image rights protection space as the overall cloud-based digital rights management market continues to grow from $491.5 million in 2016 to just over $2.5 billion by 2025 (according to a ResearchNReports study).
RYDE CEO , Jan Denecke, said, "We are very excited about our partnership with Image Protect. Together, we will continue to help protect digital storytellers worldwide. Additional cases provided by Image Protect ultimately compliment and fortify our presence in North America, Europe and SE Asia.”
The Partnership will be implemented over the coming quarter, with infringement identification, settlements, and revenues targeted to commence immediately.
Market Outlook:
CNBC Report Reveals Digital Ad Revenue Experienced 21.8% Boost in 2018, Eclipsing 2017 Revenues of $88.3 Billion
According to a CNBC.com report, digital ad growth has bolstered over $100 Billion from advertisers seeking massive audiences and targeting tech giants like Google and Facebook .
“The momentum behind this paradigm shift represents a tremendous opportunity for our Company, Rightsholders, and shareholders,” stated Matthew Goldman, Image Protect Co-CEO. “It’s not often when timing and opportunity meet simultaneously. In consideration of our launch in the industry, we firmly believe that the window of opportunity is now.” He concluded: “Standing on the threshold of a revolutionized industry, we view our growth potential to be considerably higher than we’ve ever experienced with the Copyright model.”
The new report states internet advertising revenues in the U.S. totaled $107.5 billion for full-year 2018 — the first time that figure has topped $100 billion. The report, commissioned by the Interactive Advertising Bureau ( IAB ) and conducted by PwC, said revenue in 2018 was 21.8% higher than full-year 2017 revenue of $88.3 billion. That double-digit growth in internet advertising comes as TV advertising increased 1.4% and radio grew 1% from 2017 to 2018, according to the report. Meanwhile, newspaper advertising decreased 6.9% and magazine advertising fell 2.1% in 2018 year over year.
An in-depth research report released last month forecasted the global growth of the native advertising market to 2025. Analysis of overall digital ad spend growth, combined with native advertising trends per market, globally, has revealed that native advertising spend is expected to increase by 372% from 2020 to 2025.
This represents an increase in the native advertising market from $85.83Bn in 2020 to a total global value of $402Bn by 2025. Image Protect stands uniquely positioned to immerse itself into this growing Industry by way of its extensive experience in the Photo Industry.
Technical Analysis:
We love these low-float, subpenny picks, because even the slightest move in share price can result in monster gains for traders.
IMTL has a well recorded history of showing traders some highly profitable intraday swings.
It is also trading just slightly above its 52-week low, which leads us to believe that its upside potential far outweighs its downside risk.
In fact, a run back to its 52-week high of $0.035 from today's alert price would net traders over +733% in pure profit!
We've done our very own chart analysis, and see the potential for a move of +161%!
The Bottom Line
As we stated above, we don't think IMTL is going to be a subpenny stock for much longer.
The Company is operating in a multi-billion dollar sector, and is set to launch game changing technology in just a few weeks on August 1st.
This could be one of your last chances to grab up shares for under a penny.
That being said, we ask that all members start their research on IMTL immediately, and consider building a position tomorrow morning at 9:30AM EST
(*Remember to use a Basic Stop-Loss Order or more advanced Stop Limit Order to protect your gains, as well as limit possible losses.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by ACN LLC for a 1-day investor relations advertising marketing campaign w/ 1000 TradingView™ views for IMTL . We have been previously compensated ten thousand dollars by ACN LLC to conduct investor relations advertising and marketing for IMTL-which has expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Orion Group Holdings on a bull run.
HAVING RECEIVED A BULLISH UPGRADE TO $5 THE STOCK RALLIED 18% IN WHAT WAS A PRETTY POOR DAY IN THE MARKET. IT WILL BE ADDED TO THE WATCHLIST FOR CONTINUATION, ALTHOUGH IT IS OVERBOUGHT AS A RESULT OF THE RECENT RALLY.
AVERAGE PRICE TARGET $5.55
AVERAGE RECOMMENDATION OVERWEIGHT
COMPANY PROFILE
Orion Group Holdings , Inc. engages in the provision of specialty construction services in the building, industrial, and infrastructure sectors. It operates through the Marine and Concrete segments. The Marine segment includes the restoration, maintenance, dredging, and repair of marine transportation facilities; pipelines, bridges, and causeways; and environmental structures. The Concrete segment involves cement pouring for products such as columns, elevated beams, sidewalks, ramps, and tilt walls. The company was founded in 1994 and is headquartered in Houston, TX .
Orion Group Holdings on a bull run.
HAVING RECEIVED A BULLISH UPGRADE TO $5 THE STOCK RALLIED 18% IN WHAT WAS A PRETTY POOR DAY IN THE MARKET. IT WILL BE ADDED TO THE WATCHLIST FOR CONTINUATION, ALTHOUGH IT IS OVERBOUGHT AS A RESULT OF THE RECENT RALLY.
AVERAGE PRICE TARGET $5.55
AVERAGE RECOMMENDATION OVERWEIGHT
COMPANY PROFILE
Orion Group Holdings , Inc. engages in the provision of specialty construction services in the building, industrial, and infrastructure sectors. It operates through the Marine and Concrete segments. The Marine segment includes the restoration, maintenance, dredging, and repair of marine transportation facilities; pipelines, bridges, and causeways; and environmental structures. The Concrete segment involves cement pouring for products such as columns, elevated beams, sidewalks, ramps, and tilt walls. The company was founded in 1994 and is headquartered in Houston, TX .
MAYO CLINIC PURCHASES $1 MILLION OF BIOSIG TECHNOLOGIES
Biosig Technologies Has recently joined the Russell 3000 and they signs are that it has brought a change of fortunes and should / will attract new investors, after hours today we are made aware that Mayo Clinic http://www.mayoclinic.org/ purchased $1 million in stock which is a strong vote of confidence.
This stock is well worth keeping on your watchlist.
COMPANY PROFILE
BioSig Technologies, Inc. operates as a medical device company. It engages in the development of proprietary biomedical signal processing technology platform to minimize noise and artifacts from cardiac recordings. The company develops and designs the precise uninterrupted real-time evaluation of electrograms electrophysiology (EP) system which acquires, processes, and displays electrocardiogram and electrograms required during EP studies and ablation procedures. BioSig Technologies was founded by Lora Mikolaitis, Budimir S. Drakulic and Kenneth L. Londoner on February 24, 2009 and is headquartered in Los Angeles, CA.
MAYO CLINIC PURCHASES $1 MILLION OF BIOSIG TECHNOLOGIES
Biosig Technologies Has recently joined the Russell 3000 and they signs are that it has brought a change of fortunes and should / will attract new investors, after hours today we are made aware that Mayo Clinic http://www.mayoclinic.org/ purchased $1 million in stock which is a strong vote of confidence.
This stock is well worth keeping on your watchlist.
COMPANY PROFILE
BioSig Technologies, Inc. operates as a medical device company. It engages in the development of proprietary biomedical signal processing technology platform to minimize noise and artifacts from cardiac recordings. The company develops and designs the precise uninterrupted real-time evaluation of electrograms electrophysiology (EP) system which acquires, processes, and displays electrocardiogram and electrograms required during EP studies and ablation procedures. BioSig Technologies was founded by Lora Mikolaitis, Budimir S. Drakulic and Kenneth L. Londoner on February 24, 2009 and is headquartered in Los Angeles, CA.
OWENS & MINOR INC STARTS TO TURNAROUND
OMI has a great reversal of the bottom and indications are that there is more to come. We keep this tock on the watchlist for continued strong volume and alerts are set for a MACD crossing the xzero line.
AVERAGE ANALYSTS PRICE TARGET $4
AVERAGE RECOMMENDATION UNDERWEIGHT
SHORT INTEREST 22%
COMPANY PROFILE
Owens & Minor , Inc. engages in provision of services to the manufacturers of healthcare products, supplies, and devices. It operates through the Global Solutions and Global Products segments. The Global Solutions segment includes United States and European distribution, logistics and value-added services business. The Global Products segment manufactures and sources medical surgical products through production and kitting operations. The company was founded by Otho O. Owens and G. Gilmer Minor in 1882 and is headquartered in Mechanicsville, VA .
OWENS & MINOR INC STARTS TO TURNAROUND
OMI has a great reversal of the bottom and indications are that there is more to come. We keep this tock on the watchlist for continued strong volume and alerts are set for a MACD crossing the xzero line.
AVERAGE ANALYSTS PRICE TARGET $4
AVERAGE RECOMMENDATION UNDERWEIGHT
SHORT INTEREST 22%
COMPANY PROFILE
Owens & Minor , Inc. engages in provision of services to the manufacturers of healthcare products, supplies, and devices. It operates through the Global Solutions and Global Products segments. The Global Solutions segment includes United States and European distribution, logistics and value-added services business. The Global Products segment manufactures and sources medical surgical products through production and kitting operations. The company was founded by Otho O. Owens and G. Gilmer Minor in 1882 and is headquartered in Mechanicsville, VA .
Bitcoin Adoption Phase 1.618 Target
This is not financial advice just an observation with some basic TA. One big fundamental element is starting to increase with Bitcoin and that is use-case. We have not really had it until possibly the last year or so, more blockchains, more use-cases for cryptocurrency and bigger players starting to jump into the market.
We believe that a long-term investment is still a good one, but timing is key. There is no time limit on this but a lot of people are starting to get excited about the prospect of Bitcoin and its future value.
Bitcoin Adoption Phase 1.618 Target
This is not financial advice just an observation with some basic TA. One big fundamental element is starting to increase with Bitcoin and that is use-case. We have not really had it until possibly the last year or so, more blockchains, more use-cases for cryptocurrency and bigger players starting to jump into the market.
We believe that a long-term investment is still a good one, but timing is key. There is no time limit on this but a lot of people are starting to get excited about the prospect of Bitcoin and its future value.
BTC Pullback Complete? Retest of YTD Highs?
Is the retracement complete? Well, a pullback on the Fibonacci to the 0.65 levels is a good indication.
Bitcoin is pretty violent at the moment, moves are big and retracements are completed fast. So stay away if you are a careful trader.
If you are looking for a long-term investment, wait for a dip.
BTC Pullback Complete? Retest of YTD Highs?
Is the retracement complete? Well, a pullback on the Fibonacci to the 0.65 levels is a good indication.
Bitcoin is pretty violent at the moment, moves are big and retracements are completed fast. So stay away if you are a careful trader.
If you are looking for a long-term investment, wait for a dip.
BTC One Final Step Before YTD High Retest
BTC has a habit of being wild, although it being a lull day today due to independence day, BTC is in a good place with good support below it to go for a retest
We expect a possible test of 12,300 first and then go from there. But with it finding a good support area from the fib and now on the pivot point as support, it does look heavily.
BTC One Final Step Before YTD High Retest
BTC has a habit of being wild, although it being a lull day today due to independence day, BTC is in a good place with good support below it to go for a retest
We expect a possible test of 12,300 first and then go from there. But with it finding a good support area from the fib and now on the pivot point as support, it does look heavily.
RLLVF could run +78% (or more) in share price today!
=====================
RLLVF (Relevium Technologies Inc.)
Alert Price: $0.06
Float: 122.64M
Website | Recent News
========================
The global nutraceutical market is estimated to be over $200 billion USD and is expected to reach $300 billion by the end of 2023.
Growing awareness regarding the consumption of healthy foods has resulted in increased demand for nutraceuticals in the U.S. The European market is driven by a steady innovation of high-performance natural ingredients used in nutraceuticals. Increasing adoption of e-commerce and growing consumer awareness through social media are further likely to augment the demand for nutraceuticals over the forecast period.
The market has witnessed an increased focus on the ingredients used for manufacturing nutraceuticals. The demand for natural products is expected to grow at a rapid pace over the next eight years as consumers perceive these products to be healthier and more effective as compared to synthetic products.
We have identified a rapidly growing micro-cap company that is already well positioned to capitalize on this multi-billion dollar market.
That company is Relevium Technologies, and it is publicly traded in three countries on three separate exchanges OTCQB: “RLLVF”, TSX.V: “RLV”, and Frankfurt: “6BX”.
About Relevium Technologies
Relevium Technologies operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operations of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products.
Relevium’s products are part of the $3.72 trillion dollar global wellness industry — one of the fastest growing worldwide markets. Their specific focus is on products that promote overall health, nutraceuticals, fitness nutrition and cosmeceuticals. The company already has 25 products being sold on Amazon with more being planned.
Relevium operates through two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including such as Walmart.com and Amazon.com.
The company’s product offering includes cutting-edge line of weight-loss, anti-inflammatory, heart, vision, beauty and fitness supplements sold through their Bioganix®, Push & Pull System® and LeefyLyfe® brands with the objective of helping people lose weight, become healthier, happier, and most importantly achieve the results that our customers desire.
Bioganix®, founded in 2014, has some of the best-selling products in the Health and Personal Care category on Amazon, and a loyal customer base. The combination of online marketing with an emphasis on superior quality products backed by stringent scientific research and formulations, this has developed Bioganix® in becoming one of the leading dietary supplement brands online.
Push & Pull®, launched in 2019, is the first comprehensive natural anti-aging system for complete skin care that combines Collagen Protein supplements (PUSH) and naturally sourced Aloe Vera skin anti-aging cream (PULL). This new brand targets a brand-new revenue stream in the burgeoning cosmeceutical market, which is the fastest growing segment of the health and wellness Market.
LeefyLyfe® is their OTC cannabidiol Phyto formulated brand that combines the same trusted ingredients as those found in Bioganix® and Push & Pull® with the benefits of CBD . The company is currently waiting for the decision by the FDA to allow the sale of CBD as a supplement in order to release its products into the market.
Since 2017, Relevium’s OTC has grown its product offering and expanded its distribution channels to some of the largest online marketplaces such as eBay , Amazon and Walmart.com. Relevium will continue to innovate with the BioGanix brand, expand the product line and distribution channels to further drive growth.
Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.
The company combines leading biopharma expertise, agricultural and logistic advantages of Colombia and trusted brand status with a clinically validation process for Phyto therapeutic medical products aimed at pediatric applications.
Biocannabix’ vertically integrated operations are located in key markets around the world: Canada, Colombia and Germany.
Scientific and Administrative Offices located in Montreal, Quebec
Cultivation and Extraction operations with an initial 20 hectares located in Cali , Colombia
Distribution and compliance partnership in Germany
The portfolio of Biocannabix brands include:
Cannakids®: Pediatric brand exclusive for the Canadian market
Relevium Senior®: Geriatric brand targeting inflammatory conditions including joints, heart and brain.
Relevium Kids®: Pediatric brand of Nutraceuticals and Oral Nutritional Supplements
Investment Highlights:
In 2017, the global wellness market reached $4.2T.
Global nutraceutical market to reach US$578.23B by 2025.
Vast distribution network through industry giants like Walmart and Amazon.
Building out 93,000-square-foot "Green Wave" cultivation and processing facility in Montreal, Quebec.
BioGanix generates approximately $1M in revenue per quarter.
47 SKUs developed for BioGanix to date.
Acquiring Cannakids’s IP , a leader in medical "Green Wave" patient research and pediatric and adult consumer product development.
Pending Sleipnir acquisition will initially bring in US$500K to Relevium’s topline revenue.
Partnership in place with HempCo Canada.
International expansion plans for all brands.
Recent Developments for Relevium
Relevium’s Biocannabix Positions Itself as an Important Player in Colombia as it Pursues Endo-Medical Cannabis Strategy for Latin America
Earlier this month, RLVRelevium’s Biocannabix positioned itself as an important player in the Colombian medical cannabis market by cementing medical and research relationships in the country in order to establish clinical validation programs for its Endo Nutraceutical Supplements (ENS) and Oral Nutritional Supplements.
On June 13th, 2019, the Company announced a binding LOI to acquire LifeLine Pharma SAS , a binding agreement to acquire the shares of Lifeline Pharma SAS , a Cali based cultivation and extraction business in the burgeoning agro-pharma market in Colombia. With a much lower cost of production, a robust commercial and legal framework and a culture that is open to Phyto therapeutic medicine, Colombia is quickly becoming a global center of medical cannabis supply and it is forecasted that the Country will be looking to supply as much as 44% of the World’s demand.
“This is a major strategic step in the development of our Phyto therapeutic biopharma business” stated Aurelio Useche, CEO of Relevium Technologies.
The Company’s subsidiary, Biocannabix Health Corporation, is a vertically integrated medical cannabis company with strategic positioning in three major markets: Canada, Latin America and Europe.
The company’s operations in Montreal allows Biocannabix to leverage leading edge scientific and research platforms as well as government incentives in the province of Quebec. The recent acquisition of LifeLine in Colombia allows the company to leverage lower costs of cultivation and processing as well as to manage its own genetics for the production of targeted Phyto therapeutic formulations. Colombia, Canada and Germany combined are central to the clinical validation program for the ENS and ONS products that will be offered in all three markets.
Relevium Takes Major Step in Latam to Acquire Lifeline Pharma in Cali , Colombia
Biocannabix Health Corporation (“Biocannabix”), a wholly-owned subsidiary of Relevium has executed on June 12, 2019 a binding agreement to acquire the shares of Lifeline Pharma SAS , a Cali based cultivation and extraction business in the burgeoning agro pharma market in Colombia.
KEY HIGHLIGHTS OF THE PARTNERSHIP WITH LIFELINE
Best in class partnership for international vertical integration.
Combination of Biocannabix focus on Pediatric Endo-Medicine with a large-scale operation with 150 years of sustainable, environmentally responsible and organic agricultural history
Located in Rozo, Valle del Cauca, in the heart of the sugar cane enclave seven minutes away from the international airport and 10 minutes away from Cali’s downtown core and a population of over 3M people
Multi-stage project with (1) an initial 5 hectares that includes the local offices, a laboratory, a fully enclosed greenhouse for tissue culture and micropropagation and an initial cultivation of over 200,000 square feet in open air green houses, (2) an option to expand to an additional 20 hectares or 2.2 million square feet of open air greenhouse cultivation and (3) the possibility to expand to another additional 60 hectares or 6.5 million square feet of cultivation.
Full registration of 668 genetic strains with the ICA , the Instituto Colombiano Agropecuario.
Three licenses in progress including (1) extraction and manufacturing, (2) cultivation with THC and (3) non-psychoactive cultivation, all with scientific research, domestic sales and export modalities.
Strategic low-cost infrastructure that allows for an estimated stage two flower capacity of 170,000 Kg per year with an initial estimated cost of production 0.53$ per gram.
Development of an industrial scale extraction plant in the Pacific Free Zone, a private industrial park located minutes away from the cultivation project. The free zone offers the benefits of the free regime and seeks to promote and develop the process of industrialization of goods, the productive chain and the provision of services, as well as strengthen the competitiveness of its users and customers by taking advantage of the generated opportunities from international trade and bilateral agreements signed by Colombia.
Genetics laboratory and agronomic research in the BioParque del Pacifico located in the campus of the International Center for Tropical Agriculture (CIAT) and the Colombian Corporation for agricultural research (Agrosavia).
STRATEGIC FIT FOR GLOBAL SUPPLY AND VERTICAL INTEGRATION
Relevium’s Bio-Pharma arm, Biocannabix, is focused in developing, marketing and selling endo-medicinal formulations on Nutraceuticals and Medical foods aimed primarily to pediatrics. An essential component of the strategy of delivering safe, 100% auditable medicine for pediatric patients is to ensure total control over the genetics, the cultivation and the processing of extracts. The partnership with Lifeline ensures a 100% organically grown product with access to over 600 registered genetic strains, the buildout of an EU GMP extraction facility in the Pacific Free Zone and the ability to trace and fully audit the process from seed to medicine through blockchain technology.
The strict regulation of the Colombian legal regime for cannabis only allow for the export of extracts and finished goods and we aim to service international demand for organically sourced medical cannabis extracts for LATAM, Europe and eventually the Asian continent.
LOCAL MARKET THAT IS READY TO ADOPT ENDO-MEDICINAL FORMULATIONS
Traditional remedies and natural medicine are an integral part of Colombian culture and with a fast-growing middle class and entrepreneurial nature, this market with a population of over 49 million is moving quickly to adopt cannabinoid therapy. Lifeline, through Biocannabix pediatric formulations, is poised to successfully obtain a significant market share of the local market.
TRANSACTION DETAILS
Under the terms of the binding agreement, Biocannabix will acquire 100% of the shares on Lifeline Pharma SAS by investing an initial US$850,000 to be deployed during stage one of the projects. The initial investment is comprised of US$125,000 at signing, US$125,000 upon the grant of the initial licenses and a commitment to deploy funds totalling US$600,000 over the next seven months. As part of the transaction, Biocannabix Health Corporation will issue US$3,650,000 in shares representing approximately 41% of the shares outstanding of the wholly owned subsidiary.
In the event of a major transaction including a sale or a public offering, the shareholders of Lifeline Pharma will also receive an additional US$1.5 million to be settled in shares of Biocannabix or in cash.
Aurelio Useche, CEO of Relevium stated: “The acquisition and partnership with Lifeline Pharma SAS in Colombia represents the single most important development to date for Relevium, our team and our shareholders. This is the culmination of months of strategic re-alignment, negotiations and a lot of hard work by our team and the key stakeholders of Lifeline”. Mr. Useche added:” We are very pleased and proud to partner with the amazing team of Lifeline, including Oscar LIbreros CEO and Hossein Shadanlou COO and look forward to work together to execute on the common mission of providing safe, organically sourced and fully auditable endo-medicinal products for pediatric applications”
Oscar LIbreros, CEO of Lifeline Pharma SAS stated: “With over 150 years of tradition in organic farming and our objective to provide the best medical cannabis extracts and products, we are happy (THRILLED) to join forces and merge with Biocannabix Health Corporation in Canada. We look forward to delivering real value through the disciplined deployment of our operational strategy from Colombia to the world”
Cannabis Cultivation and Extraction Potentially Costs 80% Less in Latin America
With a much lower cost of production, a robust commercial and legal framework and a culture that is open to Phyto therapeutic medicine, Colombia is quickly becoming a global center of medical cannabis supply and it is forecasted that the Country will be looking to supply as much as 44% of the World's demand.
The region boasts exceptional climatic conditions, with lots of sunshine and good rainfall. This coupled with acres and acres of arable land, could make the LATAM region the global leaders in cannabis production.
In addition to the above, the price of labor is exceptionally cheap when compared to it's European and North American counterparts. Combined, it is estimated that LATAM will be able to produce cannabis – in commercial quantities – for nearly 80% less than the rest of the world. That's a pretty big advantage.
The recent acquisition of LifeLine in Colombia allows the company to leverage lower costs of cultivation and processing as well as to manage its own genetics for the production of targeted Phyto therapeutic formulations. Colombia, Canada and Germany combined are central to the clinical validation program for the ENS and ONS products that will be offered in all three markets.
We See the Potential For a +78% Move From Here
We've done our very own chart analysis, and we see the potential for a move of +78% from here.
Bullish Technical Indicators:
Well defined price channel established with respected trendlines .
Bottom hit and reversed on the daily candle.
Accumulative volume spikes.
Bounce off well defined trendline . Ready to trend higher.
Increased volume .
The Bottom Line
RLLVF deserves your immediate attention
We suggest that you add this rapidly growing micro-cap to the top of your watch-list, as these triggered technical indicators and company news could bring serious interest to this stock.
Best Regards,
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated three thousand dollars by STM LLC for an investor relations advertising marketing campaign w/ 2000 TradingView™ views for RLLVF. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
RLLVF could run +78% (or more) in share price today!
=====================
RLLVF (Relevium Technologies Inc.)
Alert Price: $0.06
Float: 122.64M
Website | Recent News
========================
The global nutraceutical market is estimated to be over $200 billion USD and is expected to reach $300 billion by the end of 2023.
Growing awareness regarding the consumption of healthy foods has resulted in increased demand for nutraceuticals in the U.S. The European market is driven by a steady innovation of high-performance natural ingredients used in nutraceuticals. Increasing adoption of e-commerce and growing consumer awareness through social media are further likely to augment the demand for nutraceuticals over the forecast period.
The market has witnessed an increased focus on the ingredients used for manufacturing nutraceuticals. The demand for natural products is expected to grow at a rapid pace over the next eight years as consumers perceive these products to be healthier and more effective as compared to synthetic products.
We have identified a rapidly growing micro-cap company that is already well positioned to capitalize on this multi-billion dollar market.
That company is Relevium Technologies, and it is publicly traded in three countries on three separate exchanges OTCQB: “RLLVF”, TSX.V: “RLV”, and Frankfurt: “6BX”.
About Relevium Technologies
Relevium Technologies operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operations of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products.
Relevium’s products are part of the $3.72 trillion dollar global wellness industry — one of the fastest growing worldwide markets. Their specific focus is on products that promote overall health, nutraceuticals, fitness nutrition and cosmeceuticals. The company already has 25 products being sold on Amazon with more being planned.
Relevium operates through two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including such as Walmart.com and Amazon.com.
The company’s product offering includes cutting-edge line of weight-loss, anti-inflammatory, heart, vision, beauty and fitness supplements sold through their Bioganix®, Push & Pull System® and LeefyLyfe® brands with the objective of helping people lose weight, become healthier, happier, and most importantly achieve the results that our customers desire.
Bioganix®, founded in 2014, has some of the best-selling products in the Health and Personal Care category on Amazon, and a loyal customer base. The combination of online marketing with an emphasis on superior quality products backed by stringent scientific research and formulations, this has developed Bioganix® in becoming one of the leading dietary supplement brands online.
Push & Pull®, launched in 2019, is the first comprehensive natural anti-aging system for complete skin care that combines Collagen Protein supplements (PUSH) and naturally sourced Aloe Vera skin anti-aging cream (PULL). This new brand targets a brand-new revenue stream in the burgeoning cosmeceutical market, which is the fastest growing segment of the health and wellness Market.
LeefyLyfe® is their OTC cannabidiol Phyto formulated brand that combines the same trusted ingredients as those found in Bioganix® and Push & Pull® with the benefits of CBD . The company is currently waiting for the decision by the FDA to allow the sale of CBD as a supplement in order to release its products into the market.
Since 2017, Relevium’s OTC has grown its product offering and expanded its distribution channels to some of the largest online marketplaces such as eBay , Amazon and Walmart.com. Relevium will continue to innovate with the BioGanix brand, expand the product line and distribution channels to further drive growth.
Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.
The company combines leading biopharma expertise, agricultural and logistic advantages of Colombia and trusted brand status with a clinically validation process for Phyto therapeutic medical products aimed at pediatric applications.
Biocannabix’ vertically integrated operations are located in key markets around the world: Canada, Colombia and Germany.
Scientific and Administrative Offices located in Montreal, Quebec
Cultivation and Extraction operations with an initial 20 hectares located in Cali , Colombia
Distribution and compliance partnership in Germany
The portfolio of Biocannabix brands include:
Cannakids®: Pediatric brand exclusive for the Canadian market
Relevium Senior®: Geriatric brand targeting inflammatory conditions including joints, heart and brain.
Relevium Kids®: Pediatric brand of Nutraceuticals and Oral Nutritional Supplements
Investment Highlights:
In 2017, the global wellness market reached $4.2T.
Global nutraceutical market to reach US$578.23B by 2025.
Vast distribution network through industry giants like Walmart and Amazon.
Building out 93,000-square-foot "Green Wave" cultivation and processing facility in Montreal, Quebec.
BioGanix generates approximately $1M in revenue per quarter.
47 SKUs developed for BioGanix to date.
Acquiring Cannakids’s IP , a leader in medical "Green Wave" patient research and pediatric and adult consumer product development.
Pending Sleipnir acquisition will initially bring in US$500K to Relevium’s topline revenue.
Partnership in place with HempCo Canada.
International expansion plans for all brands.
Recent Developments for Relevium
Relevium’s Biocannabix Positions Itself as an Important Player in Colombia as it Pursues Endo-Medical Cannabis Strategy for Latin America
Earlier this month, RLVRelevium’s Biocannabix positioned itself as an important player in the Colombian medical cannabis market by cementing medical and research relationships in the country in order to establish clinical validation programs for its Endo Nutraceutical Supplements (ENS) and Oral Nutritional Supplements.
On June 13th, 2019, the Company announced a binding LOI to acquire LifeLine Pharma SAS , a binding agreement to acquire the shares of Lifeline Pharma SAS , a Cali based cultivation and extraction business in the burgeoning agro-pharma market in Colombia. With a much lower cost of production, a robust commercial and legal framework and a culture that is open to Phyto therapeutic medicine, Colombia is quickly becoming a global center of medical cannabis supply and it is forecasted that the Country will be looking to supply as much as 44% of the World’s demand.
“This is a major strategic step in the development of our Phyto therapeutic biopharma business” stated Aurelio Useche, CEO of Relevium Technologies.
The Company’s subsidiary, Biocannabix Health Corporation, is a vertically integrated medical cannabis company with strategic positioning in three major markets: Canada, Latin America and Europe.
The company’s operations in Montreal allows Biocannabix to leverage leading edge scientific and research platforms as well as government incentives in the province of Quebec. The recent acquisition of LifeLine in Colombia allows the company to leverage lower costs of cultivation and processing as well as to manage its own genetics for the production of targeted Phyto therapeutic formulations. Colombia, Canada and Germany combined are central to the clinical validation program for the ENS and ONS products that will be offered in all three markets.
Relevium Takes Major Step in Latam to Acquire Lifeline Pharma in Cali , Colombia
Biocannabix Health Corporation (“Biocannabix”), a wholly-owned subsidiary of Relevium has executed on June 12, 2019 a binding agreement to acquire the shares of Lifeline Pharma SAS , a Cali based cultivation and extraction business in the burgeoning agro pharma market in Colombia.
KEY HIGHLIGHTS OF THE PARTNERSHIP WITH LIFELINE
Best in class partnership for international vertical integration.
Combination of Biocannabix focus on Pediatric Endo-Medicine with a large-scale operation with 150 years of sustainable, environmentally responsible and organic agricultural history
Located in Rozo, Valle del Cauca, in the heart of the sugar cane enclave seven minutes away from the international airport and 10 minutes away from Cali’s downtown core and a population of over 3M people
Multi-stage project with (1) an initial 5 hectares that includes the local offices, a laboratory, a fully enclosed greenhouse for tissue culture and micropropagation and an initial cultivation of over 200,000 square feet in open air green houses, (2) an option to expand to an additional 20 hectares or 2.2 million square feet of open air greenhouse cultivation and (3) the possibility to expand to another additional 60 hectares or 6.5 million square feet of cultivation.
Full registration of 668 genetic strains with the ICA , the Instituto Colombiano Agropecuario.
Three licenses in progress including (1) extraction and manufacturing, (2) cultivation with THC and (3) non-psychoactive cultivation, all with scientific research, domestic sales and export modalities.
Strategic low-cost infrastructure that allows for an estimated stage two flower capacity of 170,000 Kg per year with an initial estimated cost of production 0.53$ per gram.
Development of an industrial scale extraction plant in the Pacific Free Zone, a private industrial park located minutes away from the cultivation project. The free zone offers the benefits of the free regime and seeks to promote and develop the process of industrialization of goods, the productive chain and the provision of services, as well as strengthen the competitiveness of its users and customers by taking advantage of the generated opportunities from international trade and bilateral agreements signed by Colombia.
Genetics laboratory and agronomic research in the BioParque del Pacifico located in the campus of the International Center for Tropical Agriculture (CIAT) and the Colombian Corporation for agricultural research (Agrosavia).
STRATEGIC FIT FOR GLOBAL SUPPLY AND VERTICAL INTEGRATION
Relevium’s Bio-Pharma arm, Biocannabix, is focused in developing, marketing and selling endo-medicinal formulations on Nutraceuticals and Medical foods aimed primarily to pediatrics. An essential component of the strategy of delivering safe, 100% auditable medicine for pediatric patients is to ensure total control over the genetics, the cultivation and the processing of extracts. The partnership with Lifeline ensures a 100% organically grown product with access to over 600 registered genetic strains, the buildout of an EU GMP extraction facility in the Pacific Free Zone and the ability to trace and fully audit the process from seed to medicine through blockchain technology.
The strict regulation of the Colombian legal regime for cannabis only allow for the export of extracts and finished goods and we aim to service international demand for organically sourced medical cannabis extracts for LATAM, Europe and eventually the Asian continent.
LOCAL MARKET THAT IS READY TO ADOPT ENDO-MEDICINAL FORMULATIONS
Traditional remedies and natural medicine are an integral part of Colombian culture and with a fast-growing middle class and entrepreneurial nature, this market with a population of over 49 million is moving quickly to adopt cannabinoid therapy. Lifeline, through Biocannabix pediatric formulations, is poised to successfully obtain a significant market share of the local market.
TRANSACTION DETAILS
Under the terms of the binding agreement, Biocannabix will acquire 100% of the shares on Lifeline Pharma SAS by investing an initial US$850,000 to be deployed during stage one of the projects. The initial investment is comprised of US$125,000 at signing, US$125,000 upon the grant of the initial licenses and a commitment to deploy funds totalling US$600,000 over the next seven months. As part of the transaction, Biocannabix Health Corporation will issue US$3,650,000 in shares representing approximately 41% of the shares outstanding of the wholly owned subsidiary.
In the event of a major transaction including a sale or a public offering, the shareholders of Lifeline Pharma will also receive an additional US$1.5 million to be settled in shares of Biocannabix or in cash.
Aurelio Useche, CEO of Relevium stated: “The acquisition and partnership with Lifeline Pharma SAS in Colombia represents the single most important development to date for Relevium, our team and our shareholders. This is the culmination of months of strategic re-alignment, negotiations and a lot of hard work by our team and the key stakeholders of Lifeline”. Mr. Useche added:” We are very pleased and proud to partner with the amazing team of Lifeline, including Oscar LIbreros CEO and Hossein Shadanlou COO and look forward to work together to execute on the common mission of providing safe, organically sourced and fully auditable endo-medicinal products for pediatric applications”
Oscar LIbreros, CEO of Lifeline Pharma SAS stated: “With over 150 years of tradition in organic farming and our objective to provide the best medical cannabis extracts and products, we are happy (THRILLED) to join forces and merge with Biocannabix Health Corporation in Canada. We look forward to delivering real value through the disciplined deployment of our operational strategy from Colombia to the world”
Cannabis Cultivation and Extraction Potentially Costs 80% Less in Latin America
With a much lower cost of production, a robust commercial and legal framework and a culture that is open to Phyto therapeutic medicine, Colombia is quickly becoming a global center of medical cannabis supply and it is forecasted that the Country will be looking to supply as much as 44% of the World's demand.
The region boasts exceptional climatic conditions, with lots of sunshine and good rainfall. This coupled with acres and acres of arable land, could make the LATAM region the global leaders in cannabis production.
In addition to the above, the price of labor is exceptionally cheap when compared to it's European and North American counterparts. Combined, it is estimated that LATAM will be able to produce cannabis – in commercial quantities – for nearly 80% less than the rest of the world. That's a pretty big advantage.
The recent acquisition of LifeLine in Colombia allows the company to leverage lower costs of cultivation and processing as well as to manage its own genetics for the production of targeted Phyto therapeutic formulations. Colombia, Canada and Germany combined are central to the clinical validation program for the ENS and ONS products that will be offered in all three markets.
We See the Potential For a +78% Move From Here
We've done our very own chart analysis, and we see the potential for a move of +78% from here.
Bullish Technical Indicators:
Well defined price channel established with respected trendlines .
Bottom hit and reversed on the daily candle.
Accumulative volume spikes.
Bounce off well defined trendline . Ready to trend higher.
Increased volume .
The Bottom Line
RLLVF deserves your immediate attention
We suggest that you add this rapidly growing micro-cap to the top of your watch-list, as these triggered technical indicators and company news could bring serious interest to this stock.
Best Regards,
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated three thousand dollars by STM LLC for an investor relations advertising marketing campaign w/ 2000 TradingView™ views for RLLVF. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
ETH 6HR Indicating A Retest Of Highs Again
ETH looking good on the 6 Hour with the continuation of the trend.
ETH, however, keeps rejecting at the EMA 34, however looking back on the 6 hours. It has shown a good consistency with Elliot Wave theory. Looks (as it stands) about to start a third impulse wave to the upside which could break through that EMA resistance it has been hiding under for over a week now.
This is a risky trade but early indications show it is gearing up as it is ahead of BTC for the day which is uncommon, ETH usually follows Bitcoin .
ETH 6HR Indicating A Retest Of Highs Again
ETH looking good on the 6 Hour with the continuation of the trend.
ETH, however, keeps rejecting at the EMA 34, however looking back on the 6 hours. It has shown a good consistency with Elliot Wave theory. Looks (as it stands) about to start a third impulse wave to the upside which could break through that EMA resistance it has been hiding under for over a week now.
This is a risky trade but early indications show it is gearing up as it is ahead of BTC for the day which is uncommon, ETH usually follows Bitcoin .